Dendreon (DNDN) 10-K 3 Mar 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 26, 2014	Jun. 30, 2013
Document And Entity Information [Abstract]	'	'	'
Entity Registrant Name	'DENDREON CORP	'	'
Entity Central Index Key	'0001107332	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Large Accelerated Filer	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Public Float	'	'	$636,254,809
Entity Common Stock, Shares Outstanding	'	158,975,190	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$92,530	$188,408
Short-term investments	87,092	165,396
Trade accounts receivable	34,560	38,884
Inventory	54,346	76,300
Prepaid expenses and other current assets	15,220	18,302
Total current assets	283,748	487,290
Property and equipment, net	125,168	150,604
Long-term investments	19,819	76,045
Other assets	5,666	7,180
Total assets	434,401	721,119
Current liabilities:	'	'
Accounts payable	10,459	12,845
Accrued liabilities	33,619	44,821
Accrued compensation	20,144	27,050
Restructuring and contract termination liabilities	8,793	14,214
Current portion of convertible debt	27,685	'
Current portion of capital lease obligations	2,429	4,418
Current portion of facility lease obligations	632	594
Total current liabilities	103,761	103,942
Long-term accrued liabilities	5,471	5,081
Capital lease obligations, less current portion	3,575	6,219
Facility lease obligations, less current portion	10,123	10,835
Convertible senior subordinated notes due 2014	'	27,685
Convertible senior notes due 2016, net of discount	559,122	532,744
Commitments and contingencies (Note 16)	'	'
Stockholders' equity (deficit):	'	'
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding	'	'
Common stock, $0.001 par value; 250,000,000 shares authorized, 157,274,622 and 154,414,811 shares issued and outstanding at December 31, 2013 and 2012, respectively	153	150
Additional paid-in capital	2,003,271	1,988,666
Accumulated other comprehensive income	79	147
Accumulated deficit	-2,251,154	-1,954,350
Total stockholders' equity (deficit)	-247,651	34,613
Total liabilities and stockholders' equity (deficit)	$434,401	$721,119

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Stockholders' equity (deficit):	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	157,274,622	154,414,811
Common stock, shares outstanding	157,274,622	154,414,811

Consolidated_Statements_Of_Ope

Consolidated Statements Of Operations (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Consolidated Statements Of Operations [Abstract]	'	'	'
Product revenue, net	$283,676	$325,333	$213,511
Royalty and other revenue	70	197	128,102
Total revenue	283,746	325,530	341,613
Operating expenses:	'	'	'
Cost of product revenue	166,328	227,892	159,090
Loss on inventory impairment	46,246	'	'
Research and development	70,833	74,643	74,290
Selling, general and administrative	232,847	317,131	361,342
Restructuring, contract termination and asset impairment	10,519	45,667	38,587
Total operating expenses	526,773	665,333	633,309
Loss from operations	-243,027	-339,803	-291,696
Other income (expense):	'	'	'
Interest income	667	1,344	1,415
Interest expense	-54,359	-55,252	-47,705
Other income (expense)	-85	101	180
Net loss	($296,804)	($393,610)	($337,806)
Basic and diluted net loss per share	($1.95)	($2.65)	($2.31)
Shares used in computation of basic and diluted net loss per share	151,985	148,777	146,163

Consolidated_Statements_Of_Com

Consolidated Statements Of Comprehensive Income (Loss) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Consolidated Statements Of Comprehensive Income (Loss) [Abstract]	'	'	'
Net loss	($296,804)	($393,610)	($337,806)
Other comprehensive income (loss):	'	'	'
Net unrealized gain (loss) on securities	-68	182	-76
Comprehensive loss	($296,872)	($393,428)	($337,882)

Consolidated_Statements_Of_Sto

Consolidated Statements Of Stockholders' Equity (Deficit) (USD $)	Common Stock [Member]	Additional Paid In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Total
In Thousands, except Share data
Beginning Balance at Dec. 31, 2010	$145	$1,715,522	$41	($1,222,934)	$492,774
Beginning Balance, Shares at Dec. 31, 2010	147,448,208	'	'	'	'
Exercise of stock options	1	6,128	'	'	6,129
Exercise of stock options, Shares	475,225	'	'	'	475,225
Issuance of common stock under the Employee Stock Purchase Plan	'	5,872	'	'	5,872
Issuance of common stock under the Employee Stock Purchase Plan, Shares	414,589	'	'	'	'
Issuance of convertible debt	'	130,118	'	'	130,118
Non-cash stock-based compensation expense	'	58,583	'	'	58,583
Issuance of restricted stock, net of cancellations	1	-2,958	'	'	-2,957
Issuance of restricted stock, net of cancellations, Shares	831,257	'	'	'	'
Net loss	'	'	'	-337,806	-337,806
Other comprehensive income (loss)	'	'	-76	'	-76
Ending Balance at Dec. 31, 2011	147	1,913,265	-35	-1,560,740	352,637
Ending Balance, Shares at Dec. 31, 2011	149,169,279	'	'	'	'
Exercise of stock options	'	249	'	'	249
Exercise of stock options, Shares	49,551	'	'	'	49,551
Issuance of common stock under the Employee Stock Purchase Plan	1	4,129	'	'	4,130
Issuance of common stock under the Employee Stock Purchase Plan, Shares	741,159	'	'	'	'
Non-cash stock-based compensation expense	'	73,097	'	'	73,097
Issuance of restricted stock, net of cancellations	2	-2,074	'	'	-2,072
Issuance of restricted stock, net of cancellations, Shares	4,454,822	'	'	'	'
Net loss	'	'	'	-393,610	-393,610
Other comprehensive income (loss)	'	'	182	'	182
Ending Balance at Dec. 31, 2012	150	1,988,666	147	-1,954,350	34,613
Ending Balance, Shares at Dec. 31, 2012	154,414,811	'	'	'	'
Exercise of stock options	'	41	'	'	41
Exercise of stock options, Shares	8,256	'	'	'	8,256
Issuance of common stock under the Employee Stock Purchase Plan	1	1,534	'	'	1,535
Issuance of common stock under the Employee Stock Purchase Plan, Shares	483,000	'	'	'	'
Non-cash stock-based compensation expense	'	14,253	'	'	14,253
Issuance of restricted stock, net of cancellations	2	-1,223	'	'	-1,221
Issuance of restricted stock, net of cancellations, Shares	2,368,555	'	'	'	'
Net loss	'	'	'	-296,804	-296,804
Other comprehensive income (loss)	'	'	-68	'	-68
Ending Balance at Dec. 31, 2013	$153	$2,003,271	$79	($2,251,154)	($247,651)
Ending Balance, Shares at Dec. 31, 2013	157,274,622	'	'	'	'

Consolidated_Statements_Of_Cas

Consolidated Statements Of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Operating Activities:	'	'	'
Net loss	($296,804)	($393,610)	($337,806)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation expense	30,828	39,657	36,674
Non-cash stock-based compensation expense	13,999	71,673	60,261
Amortization of securities discount and premium	2,578	3,174	2,375
Amortization of convertible notes discount and debt issuance costs	28,533	26,387	23,174
Non-cash restructuring and contract termination expense	'	17,833	14,830
Loss on inventory impairment	46,246	'	'
Other	461	613	1,128
Changes in operating assets and liabilities:	'	'	'
Trade accounts receivable	4,324	-3,343	-22,862
Inventory	-23,723	2,576	-17,565
Prepaid expenses and other assets	1,764	-1,393	-28,570
Accounts payable	-2,386	5,038	-40
Accrued liabilities and compensation	-17,786	13,213	21,354
Restructuring and contract termination liabilities	-5,421	9,462	4,752
Net cash used in operating activities	-217,387	-208,720	-242,295
Investing Activities:	'	'	'
Maturities and sales of investments	214,469	219,938	286,371
Purchases of investments	-82,722	-275,235	-332,769
Purchases of property and equipment	-5,616	-18,750	-25,423
Proceeds from sale of facility	'	43,000	'
Net cash provided by (used in) investing activities	126,131	-31,047	-71,821
Financing Activities:	'	'	'
Net proceeds from issuance of convertible debt	'	'	607,129
Payments on facility lease obligations	-674	-1,060	-5,664
Payments on capital lease obligations	-4,633	-2,602	-909
Proceeds from deposits	330	4,209	2,517
Payments of security deposits	'	-1,779	-3,895
Issuance of common stock under the Employee Stock Purchase Plan	1,535	4,130	5,872
Net proceeds from the exercise of stock options	41	249	6,128
Other	-1,221	-2,072	-2,957
Net cash provided by (used) in financing activities	-4,622	1,075	608,221
Net increase (decrease) in cash and cash equivalents	-95,878	-238,692	294,105
Cash and cash equivalents at beginning of period	188,408	427,100	132,995
Cash and cash equivalents at end of period	92,530	188,408	427,100
Supplemental Disclosure of Cash Flow Information:	'	'	'
Cash paid during the period for interest	26,241	21,193	24,889
Assets acquired under facility and capital leases	'	'	$7,759

Business_Principles_Of_Consoli

Business, Principles Of Consolidation, And Basis Of Presentation	12 Months Ended
	Dec. 31, 2013
Business, Principles Of Consolidation, And Basis Of Presentation [Abstract]	'
Business, Principles Of Consolidation, And Basis Of Presentation	'
	1. BUSINESS, PRINCIPLES OF CONSOLIDATION AND BASIS OF PRESENTATION
	Business
	Dendreon Corporation (referred to as “Dendreon,” the “Company,” “we,” “us,” or “our”), a Delaware corporation, is a biotechnology company focused on the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients. Our product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating multiple types of cancers.
	PROVENGE® (sipuleucel-T), is our first commercialized product approved by the United States Food and Drug Administration (“FDA”), and is a first-in-class autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. Commercial sale of PROVENGE began in May 2010. Prostate cancer is the most common non-skin cancer among men in the United States, with over one million men currently diagnosed with the disease, and the second leading cause of cancer deaths in men in the United States. We own worldwide rights for PROVENGE.
	Principles of Consolidation
	The consolidated financial statements include the accounts of Dendreon and its direct and indirect wholly-owned subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation.
	Use of Estimates
	Our financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of these financial statements requires us to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition, inventory, investments, fair values of assets, income taxes, financing activities, accruals and other contingencies. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could differ from these estimates.
	Liquidity and Capital Resources
	We believe that our cash, cash equivalents, and short-term and long-term investments as of December 31, 2013, together with revenue generated from our commercial sales of PROVENGE and the implementation of cost saving measures, as announced on November 12, 2013, will be sufficient to meet our obligations and anticipated expenditures for at least the next 12 months. If we are unable to achieve our forecasted revenue levels or realize the cost savings expected from our recent restructuring, we will implement additional cost saving measures.

Significant_Accounting_Policie

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Significant Accounting Policies [Abstract]	'
Significant Accounting Policies	'
	2. SIGNIFICANT ACCOUNTING POLICIES
	Revenue Recognition
	We recognize revenue primarily from the sale of PROVENGE. Revenue from the sale of PROVENGE is recorded net of product returns and estimated price discounts, including rebates and chargebacks offered pursuant to mandatory federal and state government programs and to members of Group Purchasing Organizations (“GPOs”) with which we have contracts. Revenue from sales of PROVENGE is recognized upon confirmed product delivery to and issuance of a product release form to the physician. Product returns are limited to those instances in which the physician receives the product but does not infuse the product prior to expiry, either due to timing or the failure of the product to meet specifications and pass site inspection. Due to the limited usable life of PROVENGE of approximately 18 hours from the completion of the manufacturing process to patient infusion, actual return information is known and credited against sales in the month incurred.
	PROVENGE sales are direct to physician; however, we have entered into distribution agreements with several credit-worthy third-party wholesalers (the “Wholesalers”) whereby we manufacture and ship the product direct to the physician and transfer the sale of PROVENGE to the Wholesalers. Under the distribution agreements, the Wholesalers assume all bad debt risk from the physician or institution; therefore no allowance for bad debt is recorded. Under the terms of the distribution agreements, our return policy allows for the return of product that has expired or has a defect prior to delivery, product that is damaged during delivery and product that cannot be infused because it does not otherwise meet specified requirements.
	Our product is subject to certain required pricing discounts via rebates and/or chargebacks pursuant to mandatory federal and state government programs and, accordingly, revenue recognition requires estimates of rebates and chargebacks.
	We have agreements with the Centers for Medicare and Medicaid Services (“CMS”) providing for a rebate on sales to eligible Medicaid patients. The physician purchases our product at full price, and then receives reimbursement from the applicable state. The state, in turn, invoices us for the amount of the Medicaid rebate. Estimated rebates payable under Medicaid are recognized in the same period that the related revenue is recognized, resulting in a reduction in gross product revenue, and are classified as other accrued liabilities until paid. Our estimate of rebates payable is based on historical claim information. Medicaid rebates were not material for each period presented.
	We also have agreements with the Public Health Service (“PHS”), providing for a chargeback on sales to PHS-eligible providers, and Federal Supply Schedule (“FSS”) customers, including the Department of Veteran Affairs and the Department of Defense, providing for a chargeback on sales to eligible patients. Chargebacks occur when a contracted physician purchases our product at fixed contract prices that are lower than the price we charge the Wholesalers. Each Wholesaler, in turn, charges us back for the difference between the price initially paid by the Wholesaler and the contract price paid to the Wholesaler by the physician. These chargebacks are estimated and recorded in the period that the related revenue is recognized, resulting in a reduction in gross product revenue and trade accounts receivable. During the years ended December 31, 2013 and 2012, we revised our estimate of outstanding chargebacks related to PHS-eligible providers, resulting in a reduction in the chargebacks reserve and an increase in net product revenue of $2.8 million and $3.8 million, respectively.
	The following is a roll forward of our chargebacks reserve associated with the PHS and FSS programs:
		Year Ended December 31,
		2013		2012
		(in thousands)
	Beginning balance, January 1	$	3,107	$	7,065
	Current provision related to sales made in current period		15,070		16,615
	Current provision related to sales made in prior periods		—		50
	Adjustments		-2,775		-3,824
	Payments/credits		-11,862		-16,799
	Balance at December 31	$	3,540	$	3,107
	We have entered into agreements with certain GPOs that contract for the purchase of PROVENGE on behalf of their members and provide contract administration services. Beginning in July of 2012, eligible members of the GPOs purchase PROVENGE at contracted prices through a chargeback. These chargebacks are estimated and recorded in the period that the related revenue is recognized, resulting in a reduction in gross product revenue and trade accounts receivable. The following is a roll forward of our chargebacks reserve associated with the GPO programs:
		Year Ended December 31,
		2013		2012
		(in thousands)
	Beginning balance, January 1	$	182	$	—
	Current provision related to sales made in current period		11,031		779
	Payments/credits		-9,623		-597
	Balance at December 31	$	1,590	$	182
	Eligible members of the GPOs may also be entitled to receive a rebate on eligible purchases of PROVENGE at the end of each quarter. Estimated rebates and administrative fees payable to GPOs are recognized in the same period that the related revenue is recognized, resulting in a reduction in gross product revenue, and are classified as other accrued liabilities until paid. Our estimate of rebates payable is based upon information we gather related to sales of our product to eligible GPO members. The following is a roll forward of our accrued GPO rebates and administrative fees balance:
		Year Ended December 31,
		2013		2012
		(in thousands)
	Beginning balance, January 1	$	1,950	$	885
	Current provision related to sales made in current period		6,459		7,600
	Current provision related to sales made in prior periods		—		57
	Payments/credits		-6,621		-6,592
	Balance at December 31	$	1,788	$	1,950
	In the third quarter of 2011, we began receiving royalties on Merck’s sales of VICTRELIS™ (boceprevir) for the treatment of chronic hepatitis C, which was approved in May 2011. We received royalties on worldwide net sales of boceprevir pursuant to the terms of a license and collaboration agreement. Royalty revenue and royalty receivables were recorded in the period earned, in advance of collection. We recorded royalty revenue of $3.0 million during the year ended December 31, 2011, related to royalties received on sales of this product. In the fourth quarter of 2011, we sold this royalty to an unrelated third-party for $125.0 million and recognized the full amount as revenue, as we have no further obligations under the agreement. No revenue will be recorded related to this royalty in future periods.
	Cash, Cash Equivalents and Investments
	We consider investments in highly liquid instruments purchased with an original maturity at purchase of 90 days or less to be cash equivalents. The amounts are recorded at cost, which approximates fair value. Our cash equivalents and short-term and long-term investments consist principally of commercial paper, money market securities, treasury notes, agency bonds, corporate bonds/notes and certificates of deposit.
	We have classified our entire investment portfolio as available-for-sale. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported as a separate component of stockholders’ equity and included in accumulated other comprehensive income (loss). The cost of investments is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest income. Interest earned on securities is included in interest income. Gains are recognized when realized in our consolidated statements of operations. Losses are recognized when realized or when we have determined that an other-than-temporary decline in fair value has occurred.
	We periodically evaluate whether declines in fair values of our investments below their cost are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as our ability and intent to hold the investment until a forecasted recovery occurs. Additionally, we assess whether it is more likely than not we will be required to sell any investment before recovery of its amortized cost basis.
	We consider an investment with a maturity greater than twelve months from the balance sheet date as long-term and a maturity less than twelve months as short-term at the balance sheet date. The cost of securities sold is based on the specific identification method.
	Inventory
	Inventories are determined at the lower of cost or market value with cost determined under the specific identification method. We began capitalizing raw material inventory in mid-April 2009, in anticipation of the potential approval for marketing of PROVENGE in the first half of 2010. At this time, our expectation of future benefits became sufficiently high to justify capitalization of these costs, as regulatory approval was considered probable and the related costs were expected to be recoverable through the commercialization of the product. Costs incurred prior to mid-April 2009 were recorded as research and development expense in the statements of operations, which resulted in zero-cost inventory.
	For the years ended December 31, 2012 and 2011, we used $4.7 million and $18.4 million, respectively, of zero-cost inventory; no zero-cost inventory remained on hand as of June 30, 2012. As a result, cost of product revenue reflects a lower average per unit cost of raw material prior to the second half of 2012.
	We periodically evaluate our inventory for impairment by considering factors such as expiry, obsolescence and net realizable value. We review inventory for expiry risk by evaluating current and future product demand relative to inventory life. Currently, the estimated remaining life of our raw material inventory is approximately 3 years. We expect to realize the carrying value of our inventory.
	In addition, we evaluate our inventory for impairment when events and circumstances indicate that our inventory may not meet the quality specifications required to be used in commercial production. If we determine it is likely that inventory does not meet quality specifications, we record an impairment of this inventory. Refer to Note 5 – Inventory for disclosure of impairment losses recorded in 2013 related to inventory which no longer met quality specifications.
	Property and Equipment
	Property and equipment are stated at cost and are depreciated using the straight-line method over the estimated useful lives of the assets. Estimated useful lives of furniture and office equipment and laboratory and manufacturing equipment are seven years, computer equipment and software are three years and buildings are fourteen to fifteen years. Computers and equipment financed under capital leases are amortized over the shorter of the useful lives of the related assets or the lease term. Leasehold improvements are amortized over the remaining life of the lease or ten years, whichever is shorter. Included in fixed assets is the cost of internally developed software. Costs incurred during the application development stage are capitalized and amortized over the estimated useful life of the software. All other costs related to internally developed software are expensed as incurred. Construction in progress is reclassified to the appropriate fixed asset classifications and depreciated accordingly when related assets are placed in service. We capitalize interest on borrowings during the construction period of major capital projects. Capitalized interest is added to the cost of the underlying assets and is amortized accordingly.
	Impairment of Long-Lived Assets
	We periodically evaluate the carrying value of long-lived assets to be held and used when events and circumstances indicate that the carrying amount of an asset may not be recovered. When evaluating long-lived assets for impairment, we compare the carrying value of the asset to the asset's estimated undiscounted future cash flows. Impairment is recorded if the estimated future cash flows are less than the carrying value of the asset. The impairment loss recognized, if any, is the excess of the asset’s carrying value over the fair value of the long-lived asset. The determination of fair value of the assets evaluated for impairment requires the use of judgmental assumptions surrounding the amount and timing of future cash flows and the highest and best use of the assets.
	The long-lived assets at our manufacturing facilities in Atlanta, Georgia and in Orange County, California represent our most significant long-lived assets and have an average remaining estimated useful life of approximately 7.0 years.  Our determination of the cash flows used to support the recoverability of these assets requires us to estimate future revenue growth and costs of operations, requiring significant management judgments. The estimates we used to forecast the future operating results are consistent with the plans and estimates that we use to manage our business. Significant assumptions utilized in this analysis as of December 31, 2013 included maintaining our current revenue levels and successfully implementing the cost reduction measures further discussed in Note 13 – Restructuring, Contract Termination and Asset Impairment. The recoverability test is particularly sensitive to our estimates of future revenue and operating expenses. Although we believe that our current underlying assumptions supporting this assessment are reasonable, if actual product revenues do not meet the levels we have forecasted or if we do not achieve the reductions in operating expense we have forecasted, we may be required to update the assumptions in our impairment analysis. Such updates to this analysis may impact the recoverability of these assets, which may result in a material charge to our statement of operations.
	Convertible Senior Notes due 2016
	The Company’s 2.875% Convertible Senior Notes due 2016 (the “2016 Notes”), issued in the first quarter of 2011, are convertible at the option of the holder, and we may choose to satisfy conversions, if any, in cash, shares of our common stock, or a combination of cash and shares of our common stock, based on a conversion rate initially equal to 19.5160 shares of common stock per $1,000 principal amount of the 2016 Notes, which is equivalent to an initial conversion price of $51.24 per share. Should a holder of the 2016 Notes exercise their conversion option during the next twelve month period, it is our intention to satisfy the conversion with shares of common stock.
	The 2016 Notes are accounted for in accordance with Accounting Standards Codification (“ASC”) 470-20, Debt with Conversion and Other Options, under which issuers of certain convertible debt instruments that may be settled in part in cash upon conversion, are required to separately account for the liability (debt) and equity (conversion option) components of the instrument. The liability component of the 2016 Notes, as of the issuance date, was calculated by estimating the fair value of a similar liability issued at an 8.1% effective interest rate, which was determined by considering the rate of return investors would require in the Company’s debt structure. The amount of the equity component was calculated by deducting the fair value of the liability component from the principal amount of the 2016 Notes and resulted in a corresponding increase to debt discount. The debt discount is being amortized as interest expense through the earlier of the maturity date of the 2016 Notes or the date of conversions, if any.
	For details of the issuance and additional information regarding the 2016 Notes, see Note 10 – Convertible Notes.
	Debt Issuance Costs
	Debt issuance costs related to the 2016 Notes were allocated to the liability and equity components in accordance with ASC 470-20. We are amortizing the debt issuance costs allocated to the liability component of the 2016 Notes to interest expense through the earlier of the maturity date of the 2016 Notes or the date of conversions, if any. The debt issuance costs allocated to the equity component of the 2016 Notes were recorded as an offset to additional paid-in capital. See Note 10 – Convertible Notes for further details of the issuance and additional information regarding the 2016 Notes.
	Debt issuance costs related to our 4.75% Convertible Senior Subordinated Notes due 2014 (the “2014 Notes”) issued in June and July of 2007 are amortized to interest expense through the earlier of the maturity date of the 2014 Notes or the date of conversions, if any.
	Fair Value
	We measure and report at fair value our cash equivalents and investment securities. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs.
	Assets and liabilities typically recorded at fair value on a non-recurring basis include long-lived assets measured at fair value due to an impairment assessment under ASC 360-10, Property, Plant and Equipment, and asset retirement obligations initially measured under ASC 410-20, Asset Retirement and Environmental Obligations.
	Restructuring and Contract Termination Expenses
	We record a liability for costs associated with an exit or disposal activity at fair value in the period in which the liability is incurred. Employee termination benefits are accrued when the obligation is probable and estimable. Employee termination benefits are expensed at the date the employee is notified unless the employee must provide future service in excess of 60 days, in which case such benefits are expensed ratably over the future service period. For contract termination costs, we record a liability upon the later of the contract termination date or the date we cease using the rights conveyed by the contract.
	Accounting for Stock-Based Compensation
Stock-based compensation cost is estimated at the grant date based on the award’s fair value and is recognized on the accelerated method as expense over the requisite service period. The fair value of stock options and awards under our Employee Stock Purchase Plan are calculated using the Black-Scholes-Merton (“BSM”) option pricing model. The BSM model requires various judgmental assumptions regarding volatility and expected option life. If any of the assumptions used in the BSM model change significantly, stock-based compensation expense for new awards may differ materially from that recorded for existing awards.
Restricted stock awards generally vest and are expensed over two- to four-year periods. We have granted restricted stock awards and options with certain performance conditions to certain executive officers and key employees. At each reporting date, we evaluate whether achievement of the performance conditions is probable. Compensation expense is recorded over the appropriate service period based upon our assessment of accomplishing each performance provision or the occurrence of other events which may have caused the awards or options to accelerate and vest.
In the second quarter of 2013, we granted cash-settled stock appreciation rights with a two-year vest period to certain employees. These awards are classified as liabilities and are measured at fair value at each reporting date, with fair value being determined using the BSM model.
Stock-based compensation expense also requires the estimate of forfeiture rates. In 2013, we increased our estimated forfeiture rates based on our historical data, resulting in cumulative catch-up adjustments to decrease stock-based compensation expense and net loss by $7.5 million for the year ended December 31, 2013. These adjustments decreased basic and diluted net loss per share by $0.05 for the year ended December 31, 2013.
Net Loss Per Share
Basic net loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding. For the calculation of diluted net loss per share, we have excluded all outstanding stock options, unvested restricted stock and shares issuable upon potential conversion of the 2.875% Convertible Senior Notes due 2016 (the “2016 Notes”) and the 4.75% Convertible Senior Subordinated Notes due 2014 (the “2014 Notes”) from the calculation because all such securities are anti-dilutive; accordingly, diluted net loss per share is the same as basic net loss per share.
Income Taxes
Deferred taxes are measured using enacted tax rates expected to be in effect in the year(s) in which the basis difference is expected to reverse. We continue to record a valuation allowance for the full amount of deferred tax assets, which would otherwise be recorded for tax benefits relating to operating loss and tax credit carryforwards, as realization of such deferred tax assets cannot be determined to be more likely than not.
Comprehensive Income (Loss)
Comprehensive income (loss) includes charges and credits to stockholders’ equity that are not the result of transactions with stockholders. Our comprehensive loss consisted of net loss plus changes in unrealized gain or loss on investments for the years ended December 31, 2013, 2012 and 2011.
Loss Contingencies
A loss contingency is recorded if it is probable that an asset has been impaired or a liability has been incurred and the amount of the loss can be reasonably estimated. We evaluate, among other factors, the probability of an unfavorable outcome and our ability to make a reasonable estimate of the amount of the ultimate loss. Loss contingencies that we determine to be reasonably possible, but not probable, are disclosed but not recorded. Changes in these estimates could materially affect our financial position and results of operations.
Concentrations of Risk
We are subject to concentration of risk from our single-source vendors for some components necessary for PROVENGE. Our risk for single-source vendors is managed by maintaining a certain level of existing stock of components and a continued effort to establish additional suppliers.
We are also subject to concentration of risk from our investments. Our investment portfolio is maintained in accordance with our investment policy, which specifies credit quality standards, limits credit exposure to any single issuer or security issuance and defines allowable investments. Pursuant to our policy, auction rate or asset-backed securities without a guarantee by the United States government are not permitted to be purchased. The fair value of our cash equivalents and marketable securities is subject to change as a result of changes in market interest rates and investment risk related to the issuers’ credit worthiness.
We actively monitor and manage our portfolio. If necessary, we believe we are able to liquidate our investments within the next year without significant loss. We currently believe these securities are not impaired; however, it could take until the final maturity of the underlying notes to realize our investments’ recorded values. Based on expected operating cash flows and other sources of cash, we do not anticipate the potential lack of liquidity on these investments will affect our ability to execute our current business plan.
Recent Accounting Pronouncements
In February 2013, the Financial Accounting Standards Board (the “FASB”) issued an Accounting Standards Update which requires companies to provide information about the amounts reclassified from accumulated other comprehensive income to net income by component. In addition, companies are required to present, either on the face of the statements of operations or in the notes to the financial statements, significant amounts reclassified from accumulated other comprehensive income by statement of operations line item. There were no reclassifications from accumulated other comprehensive income to net income for the year ended December 31, 2013.
In June 2013, the FASB ratified Emerging Issues Task Force (“EITF”) Issue 13-C, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists,” which concludes that an unrecognized tax benefit should be presented as a reduction of a deferred tax asset when settlement in this manner is available under the tax law. We will adopt this amendment as of January 2014, and do not believe it will have an impact on financial position, results of operations or cash flows.

Investments

Investments	12 Months Ended
	Dec. 31, 2013
Investments [Abstract]	'
Investments	'
	3. INVESTMENTS
	Securities available-for-sale at cost or amortized cost and fair market value by contractual maturity were as follows:
		Cost or Amortized Cost		Fair Market Value
		(In thousands)
	December 31, 2013
	Due in one year or less	$	87,027	$	87,092
	Due after one year through two years		19,805		19,819
		$	106,832	$	106,911
	December 31, 2012
	Due in one year or less		165,295	$	165,396
	Due after one year through two years		75,999		76,045
		$	241,294	$	241,441
	Our gross realized gains and losses on sales of available-for-sale securities were not material for the years ended December 31, 2013, 2012 or 2011.
	Securities available-for-sale, short-term and long-term, consisted of the following:
		Cost or Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Market Value
		(In thousands)
	December 31, 2013
	Demand deposit	$	5,404	$	-	$	-	$	5,404
	Corporate debt securities		64,867		59		-4		64,922
	Government-sponsored enterprises		13,064		12		-		13,076
	U.S. Treasury notes		23,497		12		-		23,509
		$	106,832	$	83	$	-4	$	106,911
	December 31, 2012
	Demand deposit		5,641	$	—	$	—	$	5,641
	Corporate debt securities		104,652		91		-17		104,726
	Government-sponsored enterprises		33,438		18		—		33,456
	U.S. Treasury notes		97,563		57		-2		97,618
		$	241,294	$	166	$	-19	$	241,441
	None of the securities have been in a continuous unrealized loss position for more than 12 months as of December 31, 2013.
	Market values were determined for each individual security in the investment portfolio. We utilize third-party pricing services for all security valuations. We review the pricing methodology, including the collection of market information, used by the third-party pricing services. On a periodic basis, we also review and validate the pricing information received from the third-party providers.
	The declines in value of these investments are primarily related to changes in interest rates and are considered to be temporary in nature. We evaluate, among other things, the duration and extent to which the fair value of a security is less than its cost, the financial condition of the issuer, and our intent to sell, or whether it is more likely than not that we will be required to sell the security before recovery of the amortized cost basis. We have the ability and intent to hold these securities to maturity; therefore we do not consider these investments to be other-than-temporarily impaired as of December 31, 2013. Refer to Note 4 – Fair Value Measurements for further discussion.
	Investments securing letters of credit in the aggregate amount of $5.4 million as of December 31, 2013 and $5.6 million as of December 31, 2012 are classified as long-term investments.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Fair Value Measurements [Abstract]	'
Fair Value Measurements	'
	4. FAIR VALUE MEASUREMENTS
	We measure and report at fair value cash equivalents and investment securities (financial assets). Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The hierarchy of fair value measurements is described below:
	Level 1 —  Observable inputs for identical assets or liabilities such as quoted prices in active markets;
	Level 2 — Inputs other than quoted prices in active markets that are either directly or indirectly observable, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs); and
	Level 3 — Unobservable inputs in which little or no market data exists, therefore determined using estimates and assumptions developed by us, which reflect those that a market participant would use.
	The following summarizes financial assets measured at fair value on a recurring basis:
	Description	Balance		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)
	Assets:	(In thousands)
	December 31, 2013
	Money market	$	68,534	$	68,534	$	—
	Commercial paper		6,000				6,000
	Corporate debt securities		64,922		—		64,922
	Government-sponsored enterprises		13,076		—		13,076
	U.S. Treasury notes		23,509		—		23,509
	Total financial assets		176,041	$	68,534	$	107,507
	Add: Cash		23,400
	Total cash, cash equivalents and investments	$	199,441
	December 31, 2012
	Money market	$	184,167	$	184,167	$	—
	Corporate debt securities		104,726		—		104,726
	Government-sponsored enterprises		33,456		—		33,456
	U.S. Treasury notes		97,618		—		97,618
	Total financial assets		419,967	$	184,167	$	235,800
	Add: Cash		9,882
	Total cash, cash equivalents and investments	$	429,849
	Fixed income investment securities are valued using the market approach. We had no Level 3 financial assets for either period presented.
	The fair value of the 2016 Notes as of December 31, 2013 and December 31, 2012 was approximately $393.8 million and $471.2 million, respectively, based on the last trading prices as of the respective period end. The fair value of the 2014 Notes as of December 31, 2013 and December 31, 2012 was approximately $27.3 million and $25.3 million, respectively, based on the last trading prices as of the respective period end. Estimates of fair value for the 2016 Notes and the 2014 Notes are based on Level 2 inputs.
	The carrying amounts reflected in the consolidated balance sheets for cash, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities approximate fair value due to their short-term nature. In addition, our capital lease obligations approximate fair value based on current interest rates, which contain an element of default risk.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2013
Inventory [Abstract]	'
Inventory	'
	5. INVENTORY
	Inventories, stated at the lower of cost or market, consisted of raw materials of $54.3 million as of December 31, 2013 and $76.3 million as of December 31, 2012.
	For the year ended December 31, 2013, we recorded a charge of $46.2 million related to antigen inventory, which no longer met quality specification and was not usable for commercial production, or which was determined to be likely to fail such quality specification. This charge is included in “Loss on inventory impairment” on our consolidated statement of operations. We have insurance coverage for up to $30 million for antigen losses of the type we believe we have sustained, although reimbursement cannot be assured with certainty at this time. We have filed an insurance claim to seek recovery of these losses. We are awaiting further information and, ultimately, reimbursement from our insurance carrier. As such, we are continuing to investigate the loss and are exploring all available options for recoverability. We believe no other antigen inventory was at risk of being out of quality specification at December 31, 2013.

Prepaid_Expenses_And_Other_Cur

Prepaid Expenses And Other Current Assets	12 Months Ended
	Dec. 31, 2013
Prepaid Expenses And Other Current Assets [Abstract]	'
Prepaid Expenses And Other Current Assets	'
	6. PREPAID EXPENSES AND OTHER CURRENT ASSETS
	As of December 31, 2013 and 2012, there was $5.9 million and $8.5 million, respectively, included in “Prepaid expenses and other current assets” on the consolidated balance sheets related to costs associated with agreements to develop second source suppliers for materials used in the manufacture of PROVENGE, and to qualify a contract manufacturer for production.

Property_And_Equipment

Property And Equipment	12 Months Ended
	Dec. 31, 2013
Property And Equipment [Abstract]	'
Property And Equipment	'
	7. PROPERTY AND EQUIPMENT
	Property and equipment consisted of the following:
		December 31,
		2013		2012
		(In thousands)
	Furniture and office equipment	$	2,823	$	2,111
	Laboratory and manufacturing equipment		29,493		29,590
	Computer equipment and software		70,976		66,117
	Leasehold improvements		117,233		115,735
	Buildings		17,872		17,872
	Construction in progress		368		2,313
			238,765		233,738
	Less accumulated depreciation and amortization		-113,597		-83,134
		$	125,168	$	150,604
	The buildings under our manufacturing facility leases must be restored to original condition upon lease termination. Accordingly, we have accrued the estimated costs of dismantlement and restoration associated with these obligations. The asset retirement obligations related to manufacturing facilities in Atlanta, Georgia (the “Atlanta Facility”) and in Orange County, California (the “Orange County Facility”) are included in “Long-term accrued liabilities” on the consolidated balance sheets.
	The following is a roll forward of the asset retirement obligations:
		Year ended December 31,
		2013		2012
		(In thousands)
	Beginning balance, January 1	$	5,081	$	7,019
	Accretion		305		529
	Release related to sale of facility		-		-2,467
	Ending balance , December 31	$	5,386	$	5,081
	For further description of the facility leases refer to Note 9 – Financing Obligations and Note 16 – Commitments and Contingencies.
	In December 2010, we entered into an industrial development revenue bond transaction related to the Atlanta Facility. Pursuant to the terms of the industrial revenue bonds, we transferred title to certain fixed assets with costs of $63.3 million as of December 31, 2010, to a local governmental authority in the United States to receive a property tax abatement related to economic development. The title to these assets will revert back to us upon retirement or cancellation of the applicable bonds. These fixed assets are still recognized in the consolidated balance sheets as all risks and benefits remain with us.
	Depreciation expense, including depreciation of assets acquired through capital leases, for the years ended December 31, 2013, 2012 and 2011 was $30.8 million, $39.7 million and $36.7 million, respectively. We capitalized interest of $0.3 million and $1.2 million for the years ended December 31, 2012 and 2011, respectively. No interest was capitalized during the year ended December 31, 2013.

Accrued_Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2013
Accrued Liabilities [Abstract]	'
Accrued Liabilities	'
	8. ACCRUED LIABILITIES
	Accrued liabilities consisted of the following:
		December 31,
		2013		2012
		(In thousands)
	Deferred rent	$	6,886	$	7,875
	Inventory receipts		1,551		6,636
	Accrued consulting and other services		7,313		12,016
	Accrued clinical trials expense		3,157		2,299
	Accrued interest		8,225		8,234
	Accrued service fees and rebates		2,899		3,533
	Other accrued liabilities		3,588		4,228
		$	33,619	$	44,821

Financing_Obligations

Financing Obligations	12 Months Ended
	Dec. 31, 2013
Financing Obligations [Abstract]	'
Financing Obligations	'
	9. FINANCING OBLIGATIONS
	We lease the Orange County Facility and the Atlanta Facility, but were deemed owner of each of these manufacturing facilities during their construction periods under build-to-suit lease accounting. Upon completion of the facilities, we continued to be deemed owner, and were required to capitalize building costs related to each facility. We therefore capitalized building costs of $6.7 million related to the Orange County Facility in August 2009 and building costs of $6.4 million related to the Atlanta Facility in March 2010, and recorded corresponding financial obligations. We allocated the lease payments between the building and the land of each facility based upon estimated relative fair values. The portion of the lease payments associated with the building reduces the facility lease obligation, while the portion associated with the land is treated as payment of an operating lease obligation.
	The Orange County Facility lease obligation has an extended term of 15.5 years with an effective interest rate of 1.46%. The estimated lease term is based on an initial 10.5-year term and a 5-year renewal. The future minimum payments of the Orange County Facility lease obligation, as presented below, reflect such 15.5 year period. The Orange County Facility lease may be renewed for up to an additional 20 years beyond the estimated 15.5-year term. The remaining facility lease obligation related to this facility, based upon the estimated 15.5-year term, was $5.3 million as of December 31, 2013.
	The Atlanta Facility lease obligation has an extended term of 15.5 years with an effective interest rate of 3.37%. The estimated lease term is based on an initial 10.5-year term and a 5-year renewal. The future minimum payments of the Atlanta Facility lease obligation, as presented below, reflect such 15.5-year period. The Atlanta Facility lease may be renewed for up to an additional 20 years beyond the estimated 15.5-year term. The remaining facility lease obligation related to this facility, based upon the estimated 15.5-year term, was $5.5 million as of December 31, 2013.
	Refer to Note 16 – Commitments and Contingencies for a further description of the facility leases.
	We have entered into agreements for the lease of software licenses and equipment which have been treated as capital leases. The capital leases, with an aggregate remaining obligation at December 31, 2013 of $6.0 million, bear interest at rates ranging from 4.4% to 11.7% per year.
	Future minimum payments due under capital lease and financing obligations were as follows as of December 31, 2013:
		Capital Lease Obligations		Facility Lease Obligations
			(In thousands)
	Year ending December 31:
	2014	$	2,743	$	866
	2015		2,782		999
	2016		985		1,040
	2017		—		1,058
	2018		—		1,077
	Thereafter		—		7,365
	Total payments		6,510		12,405
	Less amount representing interest		-506		-1,650
	Present value of payments		6,004		10,755
	Less current portion of obligations		-2,429		-632
		$	3,575	$	10,123

Convertible_Notes

Convertible Notes	12 Months Ended
	Dec. 31, 2013
Convertible Notes [Abstract]	'
Convertible Notes	'
	10. CONVERTIBLE NOTES
	2016 Notes
	On January 14, 2011, we entered into an underwriting agreement with J.P. Morgan Securities LLC (the “Underwriter”) relating to the offer and sale of $540 million aggregate principal amount of 2016 Notes. Under the terms of the underwriting agreement, we granted the Underwriter an option, exercisable within 30 days of the date of the agreement, to purchase up to an additional $80 million aggregate principal amount of 2016 Notes to cover overallotments. We issued $540 million in aggregate principal amount of 2016 Notes upon the closing of the offering on January 20, 2011. Net proceeds, after payment of underwriting fees and expenses, were $528.8 million. On January 31, 2011, the Underwriter exercised the overallotment option in full, and we closed on the sale of the additional $80 million in principal amount of 2016 Notes on February 3, 2011. Net proceeds from the exercise of the overallotment option, after payment of underwriting fees and expenses, were $78.3 million.
	On January 20, 2011, we entered into the First Supplemental Indenture (the “Supplemental Indenture”) with The Bank of New York Mellon Trust Company, N.A., as trustee (the “Trustee”), to our existing Base Indenture (the “Base Indenture” and, together with the Supplemental Indenture, the “2016 Indenture”), dated as of March 16, 2007. The 2016 Indenture sets forth the rights and provisions governing the 2016 Notes. Interest at 2.875% per annum is payable on the 2016 Notes semi-annually in arrears on January 15 and July 15 of each year. Record dates for payment of interest on the 2016 Notes are each January 1 and July 1. The maturity date of the 2016 Notes is January 15, 2016, unless earlier converted.
	The 2016 Notes are convertible at the option of the holder, and we may choose to satisfy conversions, if any, in cash, shares of our common stock, or a combination of cash and shares of our common stock, based on a conversion rate initially equal to 19.5160 shares of common stock per $1,000 principal amount of 2016 Notes, which is equivalent to an initial conversion price of $51.24 per share. The conversion rate will be increased under certain circumstances described in the 2016 Indenture; however, the number of shares of common stock issued upon conversion of a 2016 Note will not exceed 27.3224 per $1,000 principal amount of 2016 Notes, subject to adjustment in accordance with the 2016 Indenture. Should a holder exercise the conversion option during the next twelve-month period, it is our intention to satisfy the conversion with shares of common stock. Consequently, the 2016 Notes are classified as a long-term liability as of December 31, 2013 and 2012.
	The conversion rate will be adjusted upon the occurrence of certain events, including stock dividends or share splits, the issuance of rights, options or warrants, spin-offs or other distribution of property, cash dividends or distributions, or tender offers or exchange offers. We will not make an adjustment to the conversion rate for any transaction described above (other than share splits or share combinations) if each holder of 2016 Notes has the right to participate in such transaction at the same time and upon the same terms as holders of common stock, and solely as a result of holding 2016 Notes, without having to convert 2016 Notes, as if a number of shares of common stock were held equal to the applicable conversion rate multiplied by the principal amount of 2016 Notes held.
	If a “fundamental change,” as defined in the 2016 Indenture, occurs, holders of 2016 Notes may require us to repurchase all or a portion of their 2016 Notes for cash at a repurchase price equal to 100% of the principal amount of 2016 Notes to be repurchased, plus any accrued and unpaid interest and other amounts due thereon. However, if a fundamental change occurs and a holder elects to convert 2016 Notes, we will, under certain circumstances, increase the applicable conversion rate for 2016 Notes surrendered for conversion by a number of additional shares of common stock, based on the date on which the fundamental change occurs or becomes effective and the price paid per share of common stock in the fundamental change as specified in the 2016 Indenture. At our option, we will satisfy our conversion obligation with cash, shares of common stock or a combination of cash and shares, unless the consideration for common stock in any fundamental change is comprised entirely of cash, in which case the conversion obligation will be paid in cash. The number of additional shares of common stock was determined such that the fair value of the additional shares would be expected to approximate the fair value of the convertible option at the date of the fundamental change.
	In addition, we may from time to time increase the conversion rate, to the extent permitted by law, by any amount for any period of time if the period is at least 20 business days and we provide 15 business days prior written notice of such increase. We may increase the conversion rate if the Board of Directors determines that such increase would avoid or diminish United States federal income tax to holders of common stock in connection with a dividend or distribution. The 2016 Indenture contains customary covenants.
	The 2016 Notes are accounted for in accordance with FASB Accounting Standards Codification 470-20 (“ASC 470-20”), Debt with Conversion and Other Options, under which issuers of certain convertible debt instruments that may be settled entirely or partially in cash upon conversion are required to separately account for the liability (debt) and equity (conversion option) components of the instrument. The liability component of the 2016 Notes, as of the issuance date, was calculated by estimating the fair value of a similar liability issued at an 8.1% effective interest rate, which was determined by considering the rate of return investors would require in the Company’s debt structure. The amount of the equity component was calculated by deducting the fair value of the liability component from the principal amount of the 2016 Notes and resulted in a corresponding debt discount. The debt discount is being amortized as interest expense through the earlier of the maturity date of the 2016 Notes or the date of conversions, if any.
	The application of ASC 470-20 resulted in the initial recognition of $132.9 million as the debt discount recorded in additional paid-in capital for the 2016 Notes. The net carrying amount of the liability component, which is recorded as a long-term liability in the consolidated balance sheets, and the remaining unamortized debt discount were as follows:
		December 31,
		2013		2012
		(In thousands)
	Aggregate principal amount of 2016 Notes	$	620,000	$	620,000
	Unamortized discount of the liability component		60,878		87,256
	Carrying amount of the liability component	$	559,122	$	532,744
	We incurred debt issuance costs of $12.9 million related to the 2016 Notes. In accordance with ASC 470-20, we allocated $10.1 million of debt issuance costs to the liability component of the 2016 Notes, and are amortizing these costs to interest expense through the earlier of the maturity date of the 2016 Notes or the date of conversions, if any. The remaining debt issuance costs of $2.8 million was allocated to the equity component of the 2016 Notes and recorded as an offset to additional paid-in capital.
	Amortization of the debt discount and debt issuance costs resulted in non-cash interest expense of $28.4 million, $26.2 million and $23.0 million for the years ended December 31, 2013, 2012 and 2011, respectively. In addition, interest expense recognized on the 2.875%  stated coupon rate was $17.8 million for each of the years ended December 31, 2013 and 2012, and $16.8 million for the year ended December 31, 2011.
	We have identified other embedded derivatives associated with the 2016 Notes and are accounting for these embedded derivatives accordingly. These embedded derivatives meet certain criteria and are therefore not required to be accounted for separately from the 2016 Notes.
	2014 Notes
	In 2007, an aggregate of $85.3 million of 2014 Notes was sold in a private placement to qualified institutional buyers. Proceeds from the offering, after deducting placement fees and expenses of $3.0 million, were $82.3 million. The 2014 Notes were issued at face principal amount and pay interest of 4.75% per annum on a semi-annual basis in arrears on June 15 and December 15 of each year. Record dates for payment of interest on the 2014 Notes are each June 1 and December 1. The maturity date of the 2014 Notes is June 15, 2014, unless earlier converted.
	In certain circumstances, additional amounts may become due as additional interest. We can elect that the sole remedy for an event of default for our failure to comply with the “reporting obligations” provisions of the indenture under which the 2014 Notes were issued (the “2014 Indenture”) for the first 180 days after the occurrence of such event of default would be for the holders of the 2014 Notes to receive additional interest on the 2014 Notes at an annual rate equal to 1% of the outstanding principal amount of the 2014 Notes.
	The 2014 Notes are convertible into our common stock at the option of the holder, initially at a conversion price of $10.28 per share, equal to a conversion rate of 97.2644 shares per $1,000 principal amount of 2014 Notes, subject to adjustment. There may be an increase in the conversion rate of the 2014 Notes under certain circumstances described in the 2014 Indenture; however, the number of shares of common stock issued will not exceed 114.2857 per $1,000 principal amount of 2014 Notes.
	If a “fundamental change,” as defined in the 2014 Indenture, occurs, holders of 2014 Notes may require us to repurchase all or a portion of their 2014 Notes for cash at a repurchase price equal to 100% of the principal amount of 2014 Notes to be repurchased, plus any accrued and unpaid interest and other amounts due thereon. However, a holder that converts 2014 Notes in connection with a fundamental change may, in some circumstances, be entitled to an increased conversion rate (i.e., a lower per share conversion price) as a make whole premium. The increased conversion rates were determined such that the fair value of the additional shares would be expected to approximate the fair value of the convertible option at the date of the fundamental change.
	In addition, the conversion rate will be adjusted upon the occurrence of certain events, including stock dividends or share splits, the issuance of rights or warrants, other distribution of property, cash dividends or distributions, or tender offers or exchange offers. We will not make an adjustment to the conversion rate for any transaction described above (other than share splits or share combinations) if each holder of 2014 Notes has the right to participate in such transaction at the same time and upon the same terms as holders of common stock, and solely as a result of holding 2014 Notes, without having to convert 2014 Notes and as if a number of shares of common stock were held equal to the applicable conversion rate multiplied by the principal amount of 2014 Notes held.
	In addition, we may from time to time increase the conversion rate, to the extent permitted by law, by any amount for any period of time if the period is at least 20 business days and we provide 15 business days prior written notice of such increase. We may increase the conversion rate if the Board of Directors determines that such increase would avoid or diminish United States federal income tax to holders of common stock in connection with a dividend or distribution. The 2014 Indenture contains customary covenants.
	As of December 31, 2013 and 2012, the aggregate principal amount of the 2014 Notes outstanding was $27.7 million. As the 2014 Notes have a contractual maturity date of June 15, 2014, the balance is classified as a current liability as of December 31, 2013. We recorded interest expense, including the amortization of debt issuance costs, related to the 2014 Notes of $1.5 million during each of the years ended December 31, 2013, 2012 and 2011.
	We have identified embedded derivatives associated with the 2014 Notes and are accounting for these embedded derivatives accordingly. These embedded derivatives meet certain criteria and are therefore not required to be accounted for separately from the 2014 Notes.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity [Abstract]	'
Stockholders' Equity	'
	11.    STOCKHOLDERS’ EQUITY
	Preferred Stock
	We currently have 10,000,000 shares, $0.001 par value, of authorized preferred stock, of which 2,500,000 shares have been designated as Series A Junior Participating Preferred Stock. No preferred stock was issued or outstanding as of December 31, 2013 or 2012.

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2013
Stock-Based Compensation [Abstract]	'
Stock-Based Compensation	'
	12. STOCK-BASED COMPENSATION
	We maintain four stock-based incentive plans under which we have granted non-qualified stock options, incentive stock options, restricted stock, restricted stock units and stock appreciation rights to employees, non-employee directors and consultants. As of December 2013, only the 2009 Plan (as defined below) remained available for future grants. We also have an Employee Stock Purchase Plan (the “ESPP”).
	We recorded stock-based compensation expense in the consolidated statements of operations as follows:
		Year Ended December 31,
		2013			2012		2011
		(in millions)
	Cost of product revenue	$	155		$	6,571	$	5,660
	Research and development		3,890			7,103		7,278
	Selling, general and administrative		9,940			55,984		42,301
	Restructuring		184			2,015		5,022
		$	14,169		$	71,673	$	60,261
	Total stock-based compensation expense recognized in the consolidated statement of operations for 2013, 2012 and 2011 increased our net loss per share by $0.09,  $0.48 and $0.41, respectively.
	Equity Compensation Plans
	The 2000 Equity Incentive Plan (the “2000 Plan”) expired in February 2010; however it still governs outstanding awards issued under the 2000 Plan. The options granted under the 2000 Plan could be either incentive stock options or nonqualified stock options. Options granted under the 2000 Plan expire no later than 10 years from the date of grant.
	The 2002 Broad Based Equity Incentive Plan (the “2002 Plan”) expired in February 2012; however it still governs outstanding awards issued under the 2002 Plan. The 2002 Plan provided for the award of options, stock bonuses, and rights to acquire restricted stock. The stock options granted under the 2002 Plan are nonqualified options and expire no later than 10 years from the date of the grant. Employees, officers, members of our Board of Directors and consultants were eligible to receive awards under the 2002 Plan.
	The 2009 Equity Incentive Plan (the “2009 Plan”) will expire in 2019. In March 2012, our Board of Directors approved an increase to the number of shares reserved for issuance under the 2009 Plan from 13.2 million shares to 22.2 million shares of common stock. This increase was subsequently approved by our stockholders at the 2012 Annual Meeting. The 2009 Plan authorizes our Board of Directors to provide equity-based compensation in the form of incentive or nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based awards. Any common stock shares that are subject to option rights or stock appreciation rights are counted against this limit as one common share for every one common share subject to such option awards or stock appreciation rights and any common stock shares that are subject to awards other than option awards or stock appreciation rights are counted against this limit as 1.37 common shares for every one common share subject to such other awards. Shares issued under the 2009 Plan may be shares of original issuance or treasury shares or a combination of both. Options granted under the 2009 Plan expire no later than 10 years from the date of grant. The option price must be at least 100% of the fair value on the date of grant. Options and restricted stock awards generally become exercisable in increments over a period of four years from the date of grant, with the first increment vesting after one year. Options and restricted stock awards, however, may be granted with different vesting terms.
	In January 2012, we adopted the 2012 Equity Incentive Inducement Plan (the “2012 Plan”), pursuant to which we could issue up to 3.0 million shares of common stock to newly hired employees as a material inducement to their decision to join the company. The 2012 Plan was terminated in July 2012 upon stockholder approval of an increase in shares reserved for issuance under our 2009 Plan; however it still governs outstanding awards issued under the 2012 Plan.
	Employee Stock Purchase Plan
	In December 2012, our Board of Directors approved the 2013 Employee Stock Purchase Plan to replace the existing 2002 Employee Stock Purchase Plan. This new plan was subsequently approved by our stockholders at the 2013 Annual Meeting. The new ESPP plan has 10.0 million shares reserved for issuance. During the years ended December 31, 2013, 2012 and 2011, 0.5 million, 0.7 million and 0.4 million shares, respectively, were issued under the ESPP at weighted average prices of $3.18,  $5.57 and $14.16, respectively.
	Stock Options, Restricted Stock Awards and Employee Stock Purchases
	Stock options generally vest and are expensed over three- to four-year periods. Restricted stock awards generally vest and are expensed over two- to four-year periods. We have also granted restricted stock awards and stock options with certain performance conditions to certain executive officers and key employees. At each reporting date, we evaluate whether achievement of the performance conditions is probable. Compensation expense is recorded over the appropriate service period based upon our assessment of accomplishing each performance provision or the occurrence of other events which may cause the awards or options to accelerate and vest. For the years ended December 31, 2013, 2012 and 2011 we recognized $1.1 million, $0.2 million and $1.6 million, respectively, of compensation expense related to awards and options with performance conditions.
	In the second quarter of 2013, we granted cash-settled stock appreciation rights with a two-year vest period to certain employees. These awards are classified as liabilities and are measured at fair value at each reporting date, with fair value being determined using the BSM model. For the year ended December 31, 2013, we recognized $0.2 million of compensation expense related to cash-settled stock appreciation rights. As of December 31, 2013, we had approximately $0.4 million of unrecognized compensation expense related to our unvested cash-settled stock appreciation rights. We expect to recognize this compensation expense over a period of 1.4 years.
	As further described in Note 2 – Significant Accounting Policies, in 2013, we increased our estimated forfeiture rates based on our historical data, resulting in cumulative catch-up adjustments to decrease stock-based compensation expense by $7.5 million for the year ended December 31, 2013.
	The fair value of stock options and employee stock purchases was estimated at the date of grant using the BSM model with the following weighted average assumptions for the years ended December 31:
		Employee Stock Options							Employee Stock Purchase Plan
		2013			2012		2011		2013		2012		2011
	Weighted average estimated	$	2.95		$	5.85	$	18.42	$	3.78	$	2.23	$	12.40
	fair value per share
	Weighted Average Assumptions
	Dividend yield (a)		0.0%			0.0%		0.0%		0.0%		0.0%		0.0%
	Expected volatility (b)		85%			76%		78%		70%		41%		45%
	Risk-free interest rate (c)		1.0%			0.9%		1.9%		0.3%		0.1%		0.0%
	Expected term (d)		5.0 years			5.2 years		5.0 years		1.7 years		0.9 years		1.1 years
		(a)		We have not paid dividends in the past and do not plan to pay dividends in the near future.
		(b)		The expected stock price volatility is based on the weighted average historical volatility of our stock.
		(c)		The risk-free interest rate is based on the implied yield available on United States Treasury zero-coupon issues with a term equal to the expected life of the award on the date of grant.
	(d)The expected term of options granted represents the estimated period of time until exercise and is based on the historical weighted average term of similar awards, giving consideration to the contractual terms, vesting schedules, expectations of future employee behavior and the terms of certain peer companies.
	The following summarizes stock option activity:
			2013					2012				2011
			Shares Under Option		Weighted-Average Exercise Price			Shares Under Option	Weighted-Average Exercise Price			Shares Under Option	Weighted-Average Exercise Price
	Outstanding at January 1		3,757,704		$	18.71		2,576,079	$	25.98		2,672,972	$	23.78
	Granted		367,722			6.13		1,838,520		10.11		805,469		29.51
	Exercised		-8,256			4.98		-49,551		5.03		-475,225		12.90
	Forfeited and expired		-1,108,277			25.01		-607,344		22.65		-427,137		33.42
	Outstanding at December 31		3,008,893			15.10		3,757,704		18.71		2,576,079		25.98
	Options exercisable at December 31		1,768,392			18.62		1,707,659		24.18		1,158,475		20.10
	Shares available for future grant		6,507,055					9,630,340				7,966,724
	The aggregate intrinsic value of options outstanding and options exercisable as of December 31, 2013 was not material. The weighted-average remaining contractual term for options outstanding and options exercisable as of December 31, 2013 was 6.9 years and 5.8 years, respectively. The total intrinsic value of options exercised during the year ended December 31, 2013 was not material. The total intrinsic value of options exercised during the years ended December 31, 2012 and 2011 was $0.2 million and $9.5 million, respectively. The total fair value of options vested during 2013, 2012 and 2011 was $3.3 million, $7.1 million and $8.7 million, respectively.
	As of December 31, 2013 we had approximately $1.9 million of unrecognized compensation expense related to our unvested stock options. We expect to recognize this compensation expense over a weighted-average period of 1.2 years.
	The following summarizes restricted stock award activity:
			2013					2012				2011
			Number of Shares		Weighted-Average Grant Date Fair Value			Number of Shares	Weighted-Average Grant Date Fair Value			Number of Shares	Weighted-Average Grant Date Fair Value
	Outstanding at January 1		4,217,355		$	13.87		1,963,711	$	26.22		2,214,260	$	23.85
	Granted		3,625,005			5.66		5,734,632		10.83		1,305,265		30.10
	Vested		-2,522,920			12.32		-2,462,846		16.60		-1,165,524		21.68
	Forfeited and expired		-1,399,468			11.47		-1,018,142		13.93		-390,290		28.48
	Outstanding at December 31		3,919,972			6.94		4,217,355		13.87		1,963,711		26.22
	The total fair value of stock awards vested during 2013, 2012 and 2011 was $12.3 million, $19.5 million and $32.1 million, respectively. As of December 31, 2013, we had approximately $8.6 million in total unrecognized compensation expense related to restricted stock awards, which will be recognized over a weighted-average period of 1.1 years.
	Equity based awards (including stock options and stock awards) available for future issuances are as follows:
			Awards Available for Grant
	Balance at January 1, 2011		9,752,127
	Granted		-2,593,708
	Forfeited and expired		808,305
Balance at December 31, 2011		7,966,724
Additional shares reserved - 2009 Plan		9,000,000
Additional shares reserved - 2012 Plan		3,000,000
Granted		-9,748,353
Forfeited and expired		1,838,580
Cancelled - 2012 Plan		-2,426,611
Balance at December 31, 2012		9,630,340
Granted		-5,834,279
Forfeited and expired		2,710,994
Balance at December 31, 2013		6,507,055
Common Stock Reserved
As of December 31, 2013, shares of common stock were reserved for issuance as follows:
Convertible senior subordinated notes due 2014		2,692,765
Convertible senior notes due 2016		12,099,920
Outstanding common stock options		3,008,893
Employee stock purchase plan		9,517,000
Common stock awards		3,919,972
Available for future grant under equity plans		6,507,055
		37,745,605

Restructuring_Contract_Termina

Restructuring, Contract Termination And Asset Impairment	12 Months Ended
	Dec. 31, 2013
Restructuring, Contract Termination And Asset Impairment [Abstract]	'
Restructuring, Contract Termination And Asset Impairment	'
	13. RESTRUCTURING, CONTRACT TERMINATION AND ASSET IMPAIRMENT
	Restructuring – 2013
	On November 12, 2013, we announced that we were restructuring the Company and implementing additional cost reduction measures. As a result of this restructuring plan, we recorded restructuring charges of $1.8 million in the third and fourth quarters of 2013 related to fees associated with planning, developing and implementing the restructuring plan, and an initial restructuring charge of $7.1 million in the fourth quarter of 2013 related to severance and other termination benefits. We expect to record additional expense of $0.4 million related to severance and other termination benefits for the 2013 restructuring in the first quarter of 2014. We expect that the benefits will begin to be realized as early as the first quarter of 2014. We expect the restructuring initiatives will take up to 6 months to implement. The total net restructuring expenses of $8.9 million are included in “Restructuring, contract termination and asset impairment” on the statement of operations for the year ended December 31, 2013.
	Restructuring – 2012
	On July 30 2012, we announced that our Board of Directors had approved a strategic restructuring plan that included re-configuring our manufacturing model with the closure of the New Jersey Facility, restructuring administrative functions and strengthening commercial functions, which lowered our overall cost structure. The restructuring initiatives included a reduction in workforce of approximately 600 full-time and contractor positions. The employees affected by the workforce reduction were notified the week of September 17, 2012.
	On December 20, 2012, we announced the sale of the New Jersey Facility to Novartis for $43.0 million. As part of the agreement with Novartis, approximately 100 employees at the facility who were previously included in the workforce reduction were offered jobs with Novartis.
	As a result of this workforce reduction, we recorded a charge of $20.1 million during the year ended December 31, 2012 related to severance, other termination benefits, outplacement services and non-cash stock-based compensation due to the accelerated vesting of options and restricted stock awards of certain employees with employment agreements. This included an adjustment to reduce restructuring expense related to employee termination benefits by $0.3 million in the fourth quarter of 2012, related to employees accepting offers with Novartis. In addition, we recorded restructuring charges of $7.8 million during the year ended December 31, 2012 related to fees associated with planning and developing the restructuring plan, relocation benefits offered to employees, expenses associated with the closure of the New Jersey Facility and other related expenses. The total net restructuring expenses of $27.9 million are included in “Restructuring, contract termination and asset impairment” on the statement of operations for the year ended December 31, 2012.
	During the year ended December 31, 2013, additional charges of $1.4 million related to severance, other termination benefits and outplacement services were offset by reductions related to outplacement services and COBRA benefits not used by employees and severance and other termination benefits that will not be paid. As a result, net expense related to the 2012 workforce reduction during the year ended December 31, 2013 was not material. We recorded restructuring charges of $1.7 million during the year ended December 31, 2013 related to relocation benefits offered to employees, expenses associated with the closure of the New Jersey Facility, contract termination expenses and other related expenses. The total net restructuring expenses of $1.6 million are included in “Restructuring, contract termination and asset impairment” on the statement of operations for the year ended December 31, 2013. We do not expect to incur additional restructuring charges related to the 2012 restructuring as the implementation of these initiatives is complete.
	Asset Impairment – 2012
	As a result of our decision to close the New Jersey Facility, we recorded an impairment charge of $60.0 million during the third quarter of 2012 to reduce the net book value of the related property and equipment to estimated fair value. The estimate of fair value utilized an expected present value cash flow model, which included probability-weighted cash flows, requiring judgments and estimates related to the amount and timing of the cash flows and the highest and best use of the facility for a market participant. We applied a risk adjusted discount rate to our estimated cash flows in determining the net present value.
	Upon sale of the New Jersey Facility to Novartis in December 2012, we recorded a recovery of $47.4 million. The recovery represented the proceeds from the sale of the facility of $43.0 million, plus the release of the facility-specific lease and asset retirement obligations, less the remaining net book value of the New Jersey Facility. The net impairment loss of $12.6 million is recorded in “Restructuring, Contract Termination, and Asset Impairment” on the consolidated statement of operations for the year ended December 31, 2012.
	As a result of the strategic restructuring plan, we discontinued development of a non-essential computer software project and recorded an impairment charge of $5.3 million during the third quarter of 2012. The total non-cash impairment charge of $17.9 million is included in “Restructuring, contract termination and asset impairment” on the statement of operations for the year ended December 31, 2012.
	Restructuring – 2011
	On August 3, 2011, as a result of a decrease in anticipated revenue growth, we announced plans to reduce expenses, including workforce-related expenses, to align with our near-term manufacturing requirements. On September 2, 2011, our Board of Directors approved a reduction in force of approximately 25% of our total workforce, or approximately 500 employees. The employees affected by the reduction in force were notified the week of September 6, 2011.
	As a result of this workforce reduction, we recorded a charge of $19.4 million during 2011 related to severance, other termination benefits, outplacement services and non-cash stock-based compensation due to the accelerated vesting of options and restricted stock awards of certain employees with employment agreements. During the year ended December 31, 2012, we decreased our restructuring liability by $0.1 million related to other termination benefits, including outplacement services and COBRA benefits, not used by employees. These amounts are included in “Restructuring, contract termination and asset impairment” in the consolidated statements of operations. We did not incur additional restructuring charges in 2013 related to severance and other termination benefits in connection with the September 2011 restructuring.
	Contract Termination – 2011
	On September 1, 2011 we provided written notice to GlaxoSmithKline LLC (“GSK”) of termination of a Development and Supply Agreement (the “GSK Agreement”) effective on October 31, 2011. We entered into the GSK Agreement for the commercial production and supply of the antigen used in the manufacture of PROVENGE. We exercised our right to terminate the GSK Agreement when, after unforeseen delays, GSK failed to complete the process implementation phase on or before September 1, 2011 pursuant to the terms of the GSK Agreement. Assets included in our prepaid expense and other current assets balance related to the GSK Agreement were deemed unusable and, as such, we incurred an expense of $19.2 million, included in “Restructuring, contract termination and asset impairment” in our consolidated statement of operations for the year ended December 31, 2011.
	Refer to Note 16 – Commitments and Contingencies for disclosure of a lawsuit filed in the Durham County Superior Court of North Carolina against the Company by GSK. The Company expects to pay approximately $4.0 million in fees in connection with the termination of the GSK Agreement, which is included in the “Restructuring and contract termination liabilities” on our consolidated balance sheets at December 31, 2013 and 2012. The ultimate financial impact of the lawsuit is not yet determinable. Therefore, no additional provision for loss has been recorded in the financial statements.
	The following is a roll forward of restructuring liabilities:
	Description	Restructuring and Contract Termination Liabilities as of December 31, 2012		Charges, Net of Adjustments		Payments		Other Non-Cash Settlement		Restructuring and Contract Termination Liabilities as of December 31, 2013
		(In thousands)
	2013 Restructuring:
	Severance and other termination benefits	$	—	$	7,142	$	-2,605	$	-175	$	4,362
	Other associated costs		—		1,791		-1,502		—		289
	2012 Restructuring:
	Severance and other termination benefits		10,083		20		-10,094		-9		—
	Other associated costs		108		1,677		-1,643		—		142
	Asset impairment		—		-109		—		109		—
	2011 Restructuring:
	Contract termination costs		4,023		-2		-21		—		4,000
	Total	$	14,214	$	10,519	$	-15,865	$	-75	$	8,793
	Total restructuring charges of $10.5 million are included in “Restructuring, contract termination and asset impairment” on our consolidated statement of operations for the year ended December 31, 2013. We expect that the remaining liabilities associated with severance and other termination benefits related to the 2013 restructuring will be fully paid by mid-2014.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Taxes [Abstract]	'
Income Taxes	'
	14.    INCOME TAXES
	We recognized no income tax expense or benefit in 2013, 2012 or 2011. As of December 31, 2013, we had federal and state net operating loss carryforwards (“NOLs”) of $1.76 billion and $541.1 million, respectively, including $156.3 million of NOLs related to excess tax benefits associated with stock option exercises which are recorded directly to stockholder’s equity only when realized. We also had federal and state research and development credit carryforwards (“R&D Credits”) of $26.0 million and $2.6 million, respectively. The NOLs and R&D Credits will expire at various dates, beginning in 2014 and continuing through 2033, if not utilized.
	We are subject to United States federal and state income tax examinations for years after 2008 and 2007, respectively. However, carryforward attributes that were generated prior to 2007 may still be adjusted by a taxing authority upon examination if the attributes have been or will be used in a future period.
	We recognize interest and penalties accrued on unrecognized tax benefits, if any, as a component of income tax expense. During the years ended December 31, 2013, 2012 and 2011, we accrued no interest or penalties associated with unrecognized tax benefits.
	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of deferred tax assets and liabilities were as follows:
		December 31,
		2013		2012
		(In thousands)
	Deferred tax assets:
	Net operating loss carryforwards	$	591,145	$	521,171
	R&D credit carryforwards		28,622		27,239
	Stock-based compensation		10,188		21,239
	Fixed assets		3,838		1,157
	Other		40,383		24,716
	Total deferred tax assets	$	674,176	$	595,522
	Valuation allowance		-651,164		-562,723
	Net deferred tax assets		23,012		32,799
	Deferred tax liabilities:
	Convertible debt obligation		-23,012		-32,799
	Net deferred tax assets and liabilities	$	—	$	—
	The net deferred tax asset has been fully offset by a valuation allowance. The valuation allowance increased by $88.4 million, $143.1 million and $66.1 million during the years ended December 31, 2013, 2012 and 2011, respectively. In each of the years ended December 31, 2013, 2012 and 2011, tax deductions related to stock-based compensation expense were not recognized because of the availability of net operating losses, and therefore no financing cash flows were reported.
	Realization of deferred tax assets is dependent on future earnings, if any, the timing and amount of which are uncertain. Accordingly, the deferred tax assets have been offset by a valuation allowance. The valuation allowance relates primarily to net deferred tax assets from operating losses. Excess tax benefits associated with stock option exercises are recorded directly to stockholders’ equity only when realized. As a result, the excess tax benefits included in net operating loss carryforwards, but not reflected in deferred tax assets, for 2013 and 2012 were $156.3 million and $156.3 million, respectively.
	The American Taxpayer Relief Act of 2012 was signed into law on January 3, 2013, which retroactively extended the R&D Credit back to January 1, 2012. ASC 740 requires that the effect of tax legislation is taken into account in the interim period in which the law was enacted. Therefore, the 2012 R&D Credits are not contained in the 2012 deferred tax assets but are included in the balance as of December 31, 2013. R&D Credits related to 2012 were $1.4 million.
	The reconciliation of the total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits) were as follows:
			Year ended December 31,
		2013		2012		2011
			(In thousands)
	Balance at January 1	$	6,380	$	4,915	$	4,401
	Additions for tax positions related to current year		—		—		—
	Additions/reductions for tax positions of prior years		-2,309		1,465		514
	Settlements		—		—		—
	Balance at December 31	$	4,071	$	6,380	$	4,915
	Unrecognized tax benefits that, if recognized, would affect the annual effective tax rate were zero for each of the years ended December 31, 2013, 2012 and 2011.

Net_Loss_Per_Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2013
Net Loss Per Share [Abstract]	'
Net Loss Per Share	'
	15.    NET LOSS PER SHARE
	The computation of basic and diluted net loss per share is based on the weighted average number of shares of common stock outstanding during the year, and excludes all outstanding stock options and unvested restricted stock, as well as shares issuable upon potential conversion of the 2014 Notes and the 2016 Notes from the calculation of diluted net loss per common share, as all such securities are anti-dilutive to the computation for all periods presented. Shares excluded from the computation of diluted net loss per common share were 21.7 million, 22.8 million and 19.3 million for the years ended December 31, 2013, 2012 and 2011, respectively.
	The following table presents the calculation of basic and diluted net loss per share:
		December 31,
		2013		2012		2011
		(In thousands, except per share amounts)
	Net loss	$	-296,804	$	-393,610	$	-337,806
	Weighted average shares used in computation of basic and diluted net loss per share		151,985		148,777		146,163
	Basic and diluted net loss per share	$	-1.95	$	-2.65	$	-2.31

Commitments_And_Contingencies

Commitments And Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies [Abstract]	'
Commitments And Contingencies	'
	16. COMMITMENTS AND CONTINGENCIES
	We have a supply agreement with Fujifilm covering the commercial production of the recombinant antigen used in the manufacture of PROVENGE. The second amendment to the supply agreement extended the term of the agreement through December 31, 2018. Unless terminated, the agreement will renew automatically thereafter for additional 5-year terms. The agreement may be terminated upon written notice by us or Fujifilm at least 24 months before the end of a renewal term or by either party in the event of an uncured material breach or default by the other party.
	We had commitments as of December 31, 2013 with Fujifilm to purchase antigen of $22.7 million. We expect that payments on these commitments will continue through 2014.
	As described in Note 5 – Inventory, for the year ended December 31, 2013, we recorded a charge of $46.2 million related to antigen inventory, which no longer met quality specification and was not usable for commercial production, or which was determined to be likely to fail such quality specification. This charge is included in “Loss on inventory impairment” on our consolidated statement of operations. We have insurance coverage for up to $30 million for antigen losses of the type we believe we have sustained, although reimbursement cannot be assured with certainty at this time. We have filed an insurance claim to seek recovery of these losses.  We are awaiting further information and, ultimately, reimbursement from our insurance carrier. As such, we are continuing to investigate the loss and are exploring all available options for recoverability.  We believe no other antigen inventory was at risk of being out of quality specification at December 31, 2013.
	We have operating lease obligations related to two leases in Seattle, Washington which cover our principal corporate offices and research facility, a corporate office lease in Bridgewater, New Jersey, and the land portions of the Orange County Facility and the Atlanta Facility.
	In February 2011, we entered into a lease for office space of 179,656 square feet in Seattle, Washington with an initial term of five and a half years and one renewal term of two and a half years. In July 2012, we amended the lease to reduce the premises to 158,081 square feet. The related rent reduction took effect in November 2012. In April 2013, we amended the lease to further reduce the premises to 112,915 square feet. Rent payments related to the space relinquished in April 2013 cease effective October 2013 and August 2014. In addition, in April 2013 and November 2013, we subleased to two separate third parties 22,583 square feet each at these premises, commencing in May 2013 and December 2013, respectively, and continuing through the remaining term.
	A letter of credit was required as a security deposit on the lease.  A deposit of $1.1 million securing the letter of credit is included in long-term investments as of December 31, 2013 and 2012 on the consolidated balance sheets.
	In February 2011, we entered into a sublease for laboratory and office space of 97,365 square feet in Seattle, Washington. The lease term is for eight years. A letter of credit was required as a security deposit on the lease.  A deposit of $1.1 million securing the letter of credit is included in long-term investments as of December 31, 2013 and 2012 on the consolidated balance sheets.
	In July 2012, we entered into a lease for office space of 39,937 square feet in Bridgewater, New Jersey.  The initial lease term is for ten years, with one renewal term of five years. A letter of credit was required as a security deposit on the lease.  A deposit of $1.6 million securing the letter of credit is included in long-term investments as of December 31, 2013 and 2012 on the consolidated balance sheets.
	In August 2009, we entered into an agreement to lease the Orange County Facility, comprising approximately 184,000 square feet, for use as a manufacturing facility following build-out. The initial term is ten and a half years, expiring in December 2019, with five renewal terms of five years each. A letter of credit was required as a security deposit on the lease.  Deposits of $1.5 million and $1.7 million securing the letter of credit are included in long-term investments as of December 31, 2013 and 2012, respectively, on the consolidated balance sheets.
	In July 2009, we entered into an agreement to lease the Atlanta Facility, comprising approximately 156,000 square feet, for use as a manufacturing facility following build-out. The lease commenced when we took possession of the building upon substantial completion of construction of the building shell in March 2010. The initial term is ten and a half years, expiring in August 2020, with five renewal terms of five years each.
	We account for the Orange County Facility and the Atlanta Facility as assets with related facility lease obligations due to our significant investment in the build-out of the facilities. The lease payments are allocated to the building and land based on their estimated relative fair values. The portion of the lease related to land is treated as an operating lease. The portion of the lease related to the building is treated as a facility lease obligation as further discussed in Note 9 – Financing Obligations.
	Future minimum lease payments under non-cancelable operating leases, including the land portion of the Orange County Facility and the Atlanta Facility and the maintenance component of capital leases, at December 31, 2013, were as follows:
		Operating Leases
		(In thousands)
	Year ending December 31:
	2014	$	9,192
	2015		8,859
	2016		8,920
	2017		5,989
	2018		6,166
	Thereafter		8,266
	Total minimum lease payments	$	47,392
	Rent expense for the years ended December 31, 2013, 2012 and 2011 was $8.4 million, $9.6 million and $11.5 million, respectively.
	The Company and three current and former officers were named defendants in a consolidated putative securities class action proceeding filed in August 2011 with the United States District Court for the Western District of Washington (the “District Court”) under the caption In re Dendreon Corporation Class Action Litigation, Master Docket No. 2:11-cv-1291 JLR. As previously reported, the lawsuit was settled on stipulated terms that received final Court approval in August 2013. The settlement has become effective, and the litigation has been dismissed against all defendants with prejudice. A group of individual investors who elected to opt out of the class action settlement commenced their own action in the District Court alleging securities fraud on May 16, 2013. That action, captioned Christoph Bolling, et al. v. Dendreon Corporation, et al., Case No. 2:13-cv-0872 JLR, names the same defendant parties and alleges generally underlying facts as were asserted in the class action – i.e., that the Company made various false or misleading statements between April 29, 2010 and August 3, 2011 concerning the Company, its finances, business operations and prospects with a focus on the market launch of PROVENGE and related forecasts concerning physician adoption, and revenue from sales of PROVENGE. In addition to claims under the federal securities laws, the Bolling plaintiff group also purports to assert certain claims under Washington state law.  Based on information provided informally by plaintiffs’ counsel, the plaintiff group, which totals approximately 30 persons, purports to have purchased approximately 250,000 shares of Dendreon common stock during the relevant period, an amount that equates to under 0.5% of the estimated shares that comprised the plaintiff class in the class action.  The Bolling plaintiffs filed an amended complaint July 16, 2013. On August 9, 2013, the defendants filed a motion to dismiss plaintiffs’ amended complaint, and the Court held a hearing on that motion January 3, 2014.  On January 28, 2014, the Court issued an order granting the motion in part and denying the motion in part. Specifically, the Court dismissed plaintiffs’ claims based on the federal securities laws and the Washington Consumer Protection Act; however, the Court denied the motion as to plaintiffs’ state law claims for fraud and negligent misrepresentation. The Court granted plaintiffs 20 days leave to amend on the dismissed claims. On February 17,  2014, plaintiffs filed a Second Amended Complaint.  Defendants intend to file a motion to dismiss. The Bolling plaintiffs seek unspecified damages.  We cannot predict the outcome of the motion. In general, the Company intends to continue defending claims vigorously.
	Related to the securities lawsuits, the Company also is the subject of stockholder derivative complaints first filed in August 2011 generally arising out of the facts and circumstances that are alleged to underlie the securities action. Derivative suits filed in the District Court were consolidated into a proceeding captioned In re Dendreon Corp. Derivative Litigation, Master Docket No. 2:11-cv-1345 JLR; others were filed in the Superior Court of Washington for King County and were consolidated into a proceeding captioned In re Dendreon Corporation Shareholder Derivative Litigation, Lead Case No. 11-2-29626-1 SEA. On June 22, 2012, another derivative action was filed in the Court of Chancery of the State of Delaware, captioned Herbert Silverberg, derivatively on behalf of Dendreon Corporation v. Mitchell H. Gold, et al., Case No. 7646-VCP. The complaints filed in Washington all name as defendants the three individuals who are defendants in the securities action together with the other members of the Company’s Board of Directors. While the complaints filed in Washington assert various legal theories of liability, the lawsuits generally allege that the defendants breached fiduciary duties owed to the Company in connection with the launch of PROVENGE and by purportedly subjecting the Company to potential liability for securities fraud. The complaints also include claims against certain defendants for supposed misappropriation of Company information and insider trading; the Silverberg complaint, which names one additional former officer of the Company as a defendant, asserts only this claim. The Company filed a motion to dismiss the Silverberg action on standing grounds; that motion was denied in a decision issued by the Court of Chancery on December 31, 2013. The Company has asked the Court to stay the litigation pending the outcome of the Bolling litigation. For his part, plaintiff in the Silverberg complaint has filed a motion to establish an expedited trial schedule in the action (a motion that the Company and defendants have opposed) and has served initial discovery requests. The motions are awaiting decision, and we cannot predict their outcome. There have been no other proceedings in the Washington-based derivative actions. While the Company has certain indemnification obligations, including obligations to advance legal expense to the named defendants for defense of these lawsuits, the purported derivative lawsuits do not seek relief against the Company. Additionally, the Securities and Exchange Commission (“SEC”) is conducting a formal investigation, which the Company believes relates to some of the same issues raised in the securities and derivative actions. The Company is cooperating fully with the SEC investigation. The ultimate financial impact of these various proceedings, if any, is not yet determinable and therefore, no provision for loss, if any, has been recorded in the financial statements. With respect to all of the above-described proceedings, the Company has insurance that it believes affords coverage for much of the anticipated costs, subject to the policies’ terms and conditions.
	The Company received notice in November 2011 of a lawsuit filed in the Durham County Superior Court of North Carolina against the Company by GSK. The lawsuit purports claims for monies due and owing and breach of the Company’s obligations under the GSK Agreement terminated as of October 31, 2011. On April 9, 2013, GSK amended its complaint to add a claim for breach of North Carolina’s unfair and deceptive trade practices act. The Company does not believe the lawsuit has merit, filed a Counterclaim and Answer on January 6, 2012, and intends to defend its position vigorously. The Company expects to pay approximately $4.0 million in fees in connection with the termination of the GSK Agreement. The ultimate financial impact of the lawsuit is not yet determinable. Therefore, no additional provision for loss has been recorded in the financial statements.

Employee_Benefit_Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2013
Employee Benefit Plan [Abstract]	'
Employee Benefit Plan	'
	17.    EMPLOYEE BENEFIT PLAN
	We have a 401(k) plan for our employees who meet eligibility requirements. Eligible employees may contribute up to 60% of their eligible compensation, subject to Internal Revenue Service limitations.
	Our contributions to the plans are discretionary as determined by the Board of Directors. We contributed fifty cents for each dollar of employee contribution, up to a maximum of $4,000 per employee per year in 2013, 2012 and 2011. Employer contributions in the years ended December 31, 2013, 2012 and 2011 were $2.1 million, $3.8 million and $4.1 million, respectively.

Quarterly_Information

Quarterly Information	12 Months Ended
	Dec. 31, 2013
Quarterly Information [Abstract]	'
Quarterly Information	'
	18.    QUARTERLY INFORMATION (UNAUDITED)
	The following table summarizes the unaudited statements of operations for each quarter of 2013 and 2012:
		31-Mar			30-Jun		30-Sep		31-Dec
	2013	(In thousands, except per share amounts)
	Total revenue	$	67,594		$	73,315	$	68,002	$	74,835
	Cost of product revenue (3)		43,375			43,798		40,679		38,476
	Loss on inventory impairment (4)		—			—		6,254		39,992
	Gross profit (2)		24,205			29,488		21,049		-3,640
	Restructuring, contract termination and asset impairment expense		1,960			-304		1,188		7,675
	Net loss		-72,005			-68,842		-67,215		-88,742
	Basic and diluted net loss per share	$	-0.48		$	-0.45	$	-0.44	$	-0.58
		31-Mar			30-Jun		30-Sep		31-Dec
	2012	(In thousands, except per share amounts)
	Total revenue (1)	$	82,074		$	79,992	$	77,971	$	85,493
	Cost of product revenue		60,041			61,731		51,749		54,371
	Gross profit (2)		21,931			18,233		26,193		31,084
	Restructuring, contract termination and asset impairment expense (5)		-124			1,099		80,994		-36,302
	Net loss		-103,914			-96,137		-154,864		-38,695
	Basic and diluted net loss per share	$	-0.7		$	-0.65	$	-1.04	$	-0.26
		-1		Total revenue for the quarter ended December 31, 2012 includes a $3.8 million favorable change in estimate related to PHS chargebacks. See Note 2 – Significant Accounting Policies – Revenue Recognition.
		-2		Gross profit is calculated by subtracting cost of product revenue (including loss on inventory impairment) from product revenue.
		-3		Cost of product revenue for the quarter ended September 30, 2013 has been adjusted to exclude $6.3 million in loss on inventory impairment, which is now separately disclosed as “Loss on inventory impairment” on the consolidated statements of operations.
		-4		See Note 5 – Inventory for details of losses on inventory impairment recorded in the third and fourth quarters of 2013.
		-5		Restructuring, contract termination and asset impairment expense for the quarter ended September 30, 2012 includes impairment charges of $65.3 million related to our decision to close the New Jersey Facility and the discontinued development of a non-essential computer software project. Upon sale of the New Jersey Facility to Novartis in December 2012, restructuring, contract termination and asset impairment expense for the quarter ended December 31, 2012 includes the recovery of $47.4 million. The recovery was calculated as the proceeds from the sale of the facility of $43.0 million, plus the release of the facility-specific lease and asset retirement obligations, less the remaining net book value of the New Jersey Facility. Refer to Note 13 – Restructuring, Contract Termination and Asset Impairment.

Business_Principles_Of_Consoli1

Business, Principles Of Consolidation, And Basis Of Presentation (Policy)	12 Months Ended
	Dec. 31, 2013
Business, Principles Of Consolidation, And Basis Of Presentation [Abstract]	'
Business	'
	Business
	Dendreon Corporation (referred to as “Dendreon,” the “Company,” “we,” “us,” or “our”), a Delaware corporation, is a biotechnology company focused on the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients. Our product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating multiple types of cancers.
	PROVENGE® (sipuleucel-T), is our first commercialized product approved by the United States Food and Drug Administration (“FDA”), and is a first-in-class autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. Commercial sale of PROVENGE began in May 2010. Prostate cancer is the most common non-skin cancer among men in the United States, with over one million men currently diagnosed with the disease, and the second leading cause of cancer deaths in men in the United States. We own worldwide rights for PROVENGE.
Principles Of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of Dendreon and its direct and indirect wholly-owned subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation.
Use Of Estimates	'
	Use of Estimates
	Our financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of these financial statements requires us to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition, inventory, investments, fair values of assets, income taxes, financing activities, accruals and other contingencies. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could differ from these estimates.
Liquidity And Capital Resources	'
	Liquidity and Capital Resources
	We believe that our cash, cash equivalents, and short-term and long-term investments as of December 31, 2013, together with revenue generated from our commercial sales of PROVENGE and the implementation of cost saving measures, as announced on November 12, 2013, will be sufficient to meet our obligations and anticipated expenditures for at least the next 12 months. If we are unable to achieve our forecasted revenue levels or realize the cost savings expected from our recent restructuring, we will implement additional cost saving measures.

Significant_Accounting_Policie1

Significant Accounting Policies (Policy)	12 Months Ended
	Dec. 31, 2013
Significant Accounting Policies [Abstract]	'
Revenue Recognition	'
	Revenue Recognition
	We recognize revenue primarily from the sale of PROVENGE. Revenue from the sale of PROVENGE is recorded net of product returns and estimated price discounts, including rebates and chargebacks offered pursuant to mandatory federal and state government programs and to members of Group Purchasing Organizations (“GPOs”) with which we have contracts. Revenue from sales of PROVENGE is recognized upon confirmed product delivery to and issuance of a product release form to the physician. Product returns are limited to those instances in which the physician receives the product but does not infuse the product prior to expiry, either due to timing or the failure of the product to meet specifications and pass site inspection. Due to the limited usable life of PROVENGE of approximately 18 hours from the completion of the manufacturing process to patient infusion, actual return information is known and credited against sales in the month incurred.
	PROVENGE sales are direct to physician; however, we have entered into distribution agreements with several credit-worthy third-party wholesalers (the “Wholesalers”) whereby we manufacture and ship the product direct to the physician and transfer the sale of PROVENGE to the Wholesalers. Under the distribution agreements, the Wholesalers assume all bad debt risk from the physician or institution; therefore no allowance for bad debt is recorded. Under the terms of the distribution agreements, our return policy allows for the return of product that has expired or has a defect prior to delivery, product that is damaged during delivery and product that cannot be infused because it does not otherwise meet specified requirements.
	Our product is subject to certain required pricing discounts via rebates and/or chargebacks pursuant to mandatory federal and state government programs and, accordingly, revenue recognition requires estimates of rebates and chargebacks.
	We have agreements with the Centers for Medicare and Medicaid Services (“CMS”) providing for a rebate on sales to eligible Medicaid patients. The physician purchases our product at full price, and then receives reimbursement from the applicable state. The state, in turn, invoices us for the amount of the Medicaid rebate. Estimated rebates payable under Medicaid are recognized in the same period that the related revenue is recognized, resulting in a reduction in gross product revenue, and are classified as other accrued liabilities until paid. Our estimate of rebates payable is based on historical claim information. Medicaid rebates were not material for each period presented.
	We also have agreements with the Public Health Service (“PHS”), providing for a chargeback on sales to PHS-eligible providers, and Federal Supply Schedule (“FSS”) customers, including the Department of Veteran Affairs and the Department of Defense, providing for a chargeback on sales to eligible patients. Chargebacks occur when a contracted physician purchases our product at fixed contract prices that are lower than the price we charge the Wholesalers. Each Wholesaler, in turn, charges us back for the difference between the price initially paid by the Wholesaler and the contract price paid to the Wholesaler by the physician. These chargebacks are estimated and recorded in the period that the related revenue is recognized, resulting in a reduction in gross product revenue and trade accounts receivable. During the years ended December 31, 2013 and 2012, we revised our estimate of outstanding chargebacks related to PHS-eligible providers, resulting in a reduction in the chargebacks reserve and an increase in net product revenue of $2.8 million and $3.8 million, respectively.
	The following is a roll forward of our chargebacks reserve associated with the PHS and FSS programs:
		Year Ended December 31,
		2013		2012
		(in thousands)
	Beginning balance, January 1	$	3,107	$	7,065
	Current provision related to sales made in current period		15,070		16,615
	Current provision related to sales made in prior periods		—		50
	Adjustments		-2,775		-3,824
	Payments/credits		-11,862		-16,799
	Balance at December 31	$	3,540	$	3,107
	We have entered into agreements with certain GPOs that contract for the purchase of PROVENGE on behalf of their members and provide contract administration services. Beginning in July of 2012, eligible members of the GPOs purchase PROVENGE at contracted prices through a chargeback. These chargebacks are estimated and recorded in the period that the related revenue is recognized, resulting in a reduction in gross product revenue and trade accounts receivable. The following is a roll forward of our chargebacks reserve associated with the GPO programs:
		Year Ended December 31,
		2013		2012
		(in thousands)
	Beginning balance, January 1	$	182	$	—
	Current provision related to sales made in current period		11,031		779
	Payments/credits		-9,623		-597
	Balance at December 31	$	1,590	$	182
	Eligible members of the GPOs may also be entitled to receive a rebate on eligible purchases of PROVENGE at the end of each quarter. Estimated rebates and administrative fees payable to GPOs are recognized in the same period that the related revenue is recognized, resulting in a reduction in gross product revenue, and are classified as other accrued liabilities until paid. Our estimate of rebates payable is based upon information we gather related to sales of our product to eligible GPO members. The following is a roll forward of our accrued GPO rebates and administrative fees balance:
		Year Ended December 31,
		2013		2012
		(in thousands)
	Beginning balance, January 1	$	1,950	$	885
	Current provision related to sales made in current period		6,459		7,600
	Current provision related to sales made in prior periods		—		57
	Payments/credits		-6,621		-6,592
	Balance at December 31	$	1,788	$	1,950
	In the third quarter of 2011, we began receiving royalties on Merck’s sales of VICTRELIS™ (boceprevir) for the treatment of chronic hepatitis C, which was approved in May 2011. We received royalties on worldwide net sales of boceprevir pursuant to the terms of a license and collaboration agreement. Royalty revenue and royalty receivables were recorded in the period earned, in advance of collection. We recorded royalty revenue of $3.0 million during the year ended December 31, 2011, related to royalties received on sales of this product. In the fourth quarter of 2011, we sold this royalty to an unrelated third-party for $125.0 million and recognized the full amount as revenue, as we have no further obligations under the agreement. No revenue will be recorded related to this royalty in future periods.
Cash, Cash Equivalents And Investments	'
	Cash, Cash Equivalents and Investments
	We consider investments in highly liquid instruments purchased with an original maturity at purchase of 90 days or less to be cash equivalents. The amounts are recorded at cost, which approximates fair value. Our cash equivalents and short-term and long-term investments consist principally of commercial paper, money market securities, treasury notes, agency bonds, corporate bonds/notes and certificates of deposit.
	We have classified our entire investment portfolio as available-for-sale. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported as a separate component of stockholders’ equity and included in accumulated other comprehensive income (loss). The cost of investments is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest income. Interest earned on securities is included in interest income. Gains are recognized when realized in our consolidated statements of operations. Losses are recognized when realized or when we have determined that an other-than-temporary decline in fair value has occurred.
	We periodically evaluate whether declines in fair values of our investments below their cost are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as our ability and intent to hold the investment until a forecasted recovery occurs. Additionally, we assess whether it is more likely than not we will be required to sell any investment before recovery of its amortized cost basis.
	We consider an investment with a maturity greater than twelve months from the balance sheet date as long-term and a maturity less than twelve months as short-term at the balance sheet date. The cost of securities sold is based on the specific identification method.
Inventory	'
	Inventory
	Inventories are determined at the lower of cost or market value with cost determined under the specific identification method. We began capitalizing raw material inventory in mid-April 2009, in anticipation of the potential approval for marketing of PROVENGE in the first half of 2010. At this time, our expectation of future benefits became sufficiently high to justify capitalization of these costs, as regulatory approval was considered probable and the related costs were expected to be recoverable through the commercialization of the product. Costs incurred prior to mid-April 2009 were recorded as research and development expense in the statements of operations, which resulted in zero-cost inventory.
	For the years ended December 31, 2012 and 2011, we used $4.7 million and $18.4 million, respectively, of zero-cost inventory; no zero-cost inventory remained on hand as of June 30, 2012. As a result, cost of product revenue reflects a lower average per unit cost of raw material prior to the second half of 2012.
	We periodically evaluate our inventory for impairment by considering factors such as expiry, obsolescence and net realizable value. We review inventory for expiry risk by evaluating current and future product demand relative to inventory life. Currently, the estimated remaining life of our raw material inventory is approximately 3 years. We expect to realize the carrying value of our inventory.
	In addition, we evaluate our inventory for impairment when events and circumstances indicate that our inventory may not meet the quality specifications required to be used in commercial production. If we determine it is likely that inventory does not meet quality specifications, we record an impairment of this inventory. Refer to Note 5 – Inventory for disclosure of impairment losses recorded in 2013 related to inventory which no longer met quality specifications.
Property And Equipment	'
	Property and Equipment
	Property and equipment are stated at cost and are depreciated using the straight-line method over the estimated useful lives of the assets. Estimated useful lives of furniture and office equipment and laboratory and manufacturing equipment are seven years, computer equipment and software are three years and buildings are fourteen to fifteen years. Computers and equipment financed under capital leases are amortized over the shorter of the useful lives of the related assets or the lease term. Leasehold improvements are amortized over the remaining life of the lease or ten years, whichever is shorter. Included in fixed assets is the cost of internally developed software. Costs incurred during the application development stage are capitalized and amortized over the estimated useful life of the software. All other costs related to internally developed software are expensed as incurred. Construction in progress is reclassified to the appropriate fixed asset classifications and depreciated accordingly when related assets are placed in service. We capitalize interest on borrowings during the construction period of major capital projects. Capitalized interest is added to the cost of the underlying assets and is amortized accordingly.
Impairment Of Long-Lived Assets	'
	Impairment of Long-Lived Assets
	We periodically evaluate the carrying value of long-lived assets to be held and used when events and circumstances indicate that the carrying amount of an asset may not be recovered. When evaluating long-lived assets for impairment, we compare the carrying value of the asset to the asset's estimated undiscounted future cash flows. Impairment is recorded if the estimated future cash flows are less than the carrying value of the asset. The impairment loss recognized, if any, is the excess of the asset’s carrying value over the fair value of the long-lived asset. The determination of fair value of the assets evaluated for impairment requires the use of judgmental assumptions surrounding the amount and timing of future cash flows and the highest and best use of the assets.
	The long-lived assets at our manufacturing facilities in Atlanta, Georgia and in Orange County, California represent our most significant long-lived assets and have an average remaining estimated useful life of approximately 7.0 years.  Our determination of the cash flows used to support the recoverability of these assets requires us to estimate future revenue growth and costs of operations, requiring significant management judgments. The estimates we used to forecast the future operating results are consistent with the plans and estimates that we use to manage our business. Significant assumptions utilized in this analysis as of December 31, 2013 included maintaining our current revenue levels and successfully implementing the cost reduction measures further discussed in Note 13 – Restructuring, Contract Termination and Asset Impairment. The recoverability test is particularly sensitive to our estimates of future revenue and operating expenses. Although we believe that our current underlying assumptions supporting this assessment are reasonable, if actual product revenues do not meet the levels we have forecasted or if we do not achieve the reductions in operating expense we have forecasted, we may be required to update the assumptions in our impairment analysis. Such updates to this analysis may impact the recoverability of these assets, which may result in a material charge to our statement of operations.
Convertible Senior Notes Due 2016	'
	Convertible Senior Notes due 2016
	The Company’s 2.875% Convertible Senior Notes due 2016 (the “2016 Notes”), issued in the first quarter of 2011, are convertible at the option of the holder, and we may choose to satisfy conversions, if any, in cash, shares of our common stock, or a combination of cash and shares of our common stock, based on a conversion rate initially equal to 19.5160 shares of common stock per $1,000 principal amount of the 2016 Notes, which is equivalent to an initial conversion price of $51.24 per share. Should a holder of the 2016 Notes exercise their conversion option during the next twelve month period, it is our intention to satisfy the conversion with shares of common stock.
	The 2016 Notes are accounted for in accordance with Accounting Standards Codification (“ASC”) 470-20, Debt with Conversion and Other Options, under which issuers of certain convertible debt instruments that may be settled in part in cash upon conversion, are required to separately account for the liability (debt) and equity (conversion option) components of the instrument. The liability component of the 2016 Notes, as of the issuance date, was calculated by estimating the fair value of a similar liability issued at an 8.1% effective interest rate, which was determined by considering the rate of return investors would require in the Company’s debt structure. The amount of the equity component was calculated by deducting the fair value of the liability component from the principal amount of the 2016 Notes and resulted in a corresponding increase to debt discount. The debt discount is being amortized as interest expense through the earlier of the maturity date of the 2016 Notes or the date of conversions, if any.
	For details of the issuance and additional information regarding the 2016 Notes, see Note 10 – Convertible Notes.
Debt Issuance Costs	'
	Debt Issuance Costs
	Debt issuance costs related to the 2016 Notes were allocated to the liability and equity components in accordance with ASC 470-20. We are amortizing the debt issuance costs allocated to the liability component of the 2016 Notes to interest expense through the earlier of the maturity date of the 2016 Notes or the date of conversions, if any. The debt issuance costs allocated to the equity component of the 2016 Notes were recorded as an offset to additional paid-in capital. See Note 10 – Convertible Notes for further details of the issuance and additional information regarding the 2016 Notes.
	Debt issuance costs related to our 4.75% Convertible Senior Subordinated Notes due 2014 (the “2014 Notes”) issued in June and July of 2007 are amortized to interest expense through the earlier of the maturity date of the 2014 Notes or the date of conversions, if any.
Fair Value	'
	Fair Value
	We measure and report at fair value our cash equivalents and investment securities. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs.
	Assets and liabilities typically recorded at fair value on a non-recurring basis include long-lived assets measured at fair value due to an impairment assessment under ASC 360-10, Property, Plant and Equipment, and asset retirement obligations initially measured under ASC 410-20, Asset Retirement and Environmental Obligations.
Restructuring And Contract Termination Expenses	'
	Restructuring and Contract Termination Expenses
	We record a liability for costs associated with an exit or disposal activity at fair value in the period in which the liability is incurred. Employee termination benefits are accrued when the obligation is probable and estimable. Employee termination benefits are expensed at the date the employee is notified unless the employee must provide future service in excess of 60 days, in which case such benefits are expensed ratably over the future service period. For contract termination costs, we record a liability upon the later of the contract termination date or the date we cease using the rights conveyed by the contract.
Accounting For Stock-Based Compensation	'
	Accounting for Stock-Based Compensation
	Stock-based compensation cost is estimated at the grant date based on the award’s fair value and is recognized on the accelerated method as expense over the requisite service period. The fair value of stock options and awards under our Employee Stock Purchase Plan are calculated using the Black-Scholes-Merton (“BSM”) option pricing model. The BSM model requires various judgmental assumptions regarding volatility and expected option life. If any of the assumptions used in the BSM model change significantly, stock-based compensation expense for new awards may differ materially from that recorded for existing awards.
	Restricted stock awards generally vest and are expensed over two- to four-year periods. We have granted restricted stock awards and options with certain performance conditions to certain executive officers and key employees. At each reporting date, we evaluate whether achievement of the performance conditions is probable. Compensation expense is recorded over the appropriate service period based upon our assessment of accomplishing each performance provision or the occurrence of other events which may have caused the awards or options to accelerate and vest.
	In the second quarter of 2013, we granted cash-settled stock appreciation rights with a two-year vest period to certain employees. These awards are classified as liabilities and are measured at fair value at each reporting date, with fair value being determined using the BSM model.
	Stock-based compensation expense also requires the estimate of forfeiture rates. In 2013, we increased our estimated forfeiture rates based on our historical data, resulting in cumulative catch-up adjustments to decrease stock-based compensation expense and net loss by $7.5 million for the year ended December 31, 2013. These adjustments decreased basic and diluted net loss per share by $0.05 for the year ended December 31, 2013.
Net Loss Per Share	'
	Net Loss Per Share
	Basic net loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding. For the calculation of diluted net loss per share, we have excluded all outstanding stock options, unvested restricted stock and shares issuable upon potential conversion of the 2.875% Convertible Senior Notes due 2016 (the “2016 Notes”) and the 4.75% Convertible Senior Subordinated Notes due 2014 (the “2014 Notes”) from the calculation because all such securities are anti-dilutive; accordingly, diluted net loss per share is the same as basic net loss per share.
Income Taxes	'
	Income Taxes
	Deferred taxes are measured using enacted tax rates expected to be in effect in the year(s) in which the basis difference is expected to reverse. We continue to record a valuation allowance for the full amount of deferred tax assets, which would otherwise be recorded for tax benefits relating to operating loss and tax credit carryforwards, as realization of such deferred tax assets cannot be determined to be more likely than not.
Comprehensive Income (Loss)	'
	Comprehensive Income (Loss)
	Comprehensive income (loss) includes charges and credits to stockholders’ equity that are not the result of transactions with stockholders. Our comprehensive loss consisted of net loss plus changes in unrealized gain or loss on investments for the years ended December 31, 2013, 2012 and 2011.
Loss Contingencies	'
	Loss Contingencies
	A loss contingency is recorded if it is probable that an asset has been impaired or a liability has been incurred and the amount of the loss can be reasonably estimated. We evaluate, among other factors, the probability of an unfavorable outcome and our ability to make a reasonable estimate of the amount of the ultimate loss. Loss contingencies that we determine to be reasonably possible, but not probable, are disclosed but not recorded. Changes in these estimates could materially affect our financial position and results of operations.
Concentrations Of Risk	'
	Concentrations of Risk
	We are subject to concentration of risk from our single-source vendors for some components necessary for PROVENGE. Our risk for single-source vendors is managed by maintaining a certain level of existing stock of components and a continued effort to establish additional suppliers.
	We are also subject to concentration of risk from our investments. Our investment portfolio is maintained in accordance with our investment policy, which specifies credit quality standards, limits credit exposure to any single issuer or security issuance and defines allowable investments. Pursuant to our policy, auction rate or asset-backed securities without a guarantee by the United States government are not permitted to be purchased. The fair value of our cash equivalents and marketable securities is subject to change as a result of changes in market interest rates and investment risk related to the issuers’ credit worthiness.
	We actively monitor and manage our portfolio. If necessary, we believe we are able to liquidate our investments within the next year without significant loss. We currently believe these securities are not impaired; however, it could take until the final maturity of the underlying notes to realize our investments’ recorded values. Based on expected operating cash flows and other sources of cash, we do not anticipate the potential lack of liquidity on these investments will affect our ability to execute our current business plan.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In February 2013, the Financial Accounting Standards Board (the “FASB”) issued an Accounting Standards Update which requires companies to provide information about the amounts reclassified from accumulated other comprehensive income to net income by component. In addition, companies are required to present, either on the face of the statements of operations or in the notes to the financial statements, significant amounts reclassified from accumulated other comprehensive income by statement of operations line item. There were no reclassifications from accumulated other comprehensive income to net income for the year ended December 31, 2013.
	In June 2013, the FASB ratified Emerging Issues Task Force (“EITF”) Issue 13-C, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists,” which concludes that an unrecognized tax benefit should be presented as a reduction of a deferred tax asset when settlement in this manner is available under the tax law. We will adopt this amendment as of January 2014, and do not believe it will have an impact on financial position, results of operations or cash flows.

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Schedule Of Accrued Rebates and Administrative Fees	'
		Year Ended December 31,
		2013		2012
		(in thousands)
	Beginning balance, January 1	$	1,950	$	885
	Current provision related to sales made in current period		6,459		7,600
	Current provision related to sales made in prior periods		—		57
	Payments/credits		-6,621		-6,592
	Balance at December 31	$	1,788	$	1,950
PSS And FSS Customers [Member]	'
Schedule Of Chargebacks Reserve	'
		Year Ended December 31,
		2013		2012
		(in thousands)
	Beginning balance, January 1	$	3,107	$	7,065
	Current provision related to sales made in current period		15,070		16,615
	Current provision related to sales made in prior periods		—		50
	Adjustments		-2,775		-3,824
	Payments/credits		-11,862		-16,799
	Balance at December 31	$	3,540	$	3,107
Certain GPOs [Member]	'
Schedule Of Chargebacks Reserve	'
		Year Ended December 31,
		2013		2012
		(in thousands)
	Beginning balance, January 1	$	182	$	—
	Current provision related to sales made in current period		11,031		779
	Payments/credits		-9,623		-597
	Balance at December 31	$	1,590	$	182

Investments_Tables

Investments (Tables)	12 Months Ended
	Dec. 31, 2013
Investments [Abstract]	'
Schedule Of Available For Sale Securities	'
		Cost or Amortized Cost		Fair Market Value
		(In thousands)
	December 31, 2013
	Due in one year or less	$	87,027	$	87,092
	Due after one year through two years		19,805		19,819
		$	106,832	$	106,911
	December 31, 2012
	Due in one year or less		165,295	$	165,396
	Due after one year through two years		75,999		76,045
		$	241,294	$	241,441
Short-Term And Long-Term Securities Available-For-Sale	'
		Cost or Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Market Value
		(In thousands)
	December 31, 2013
	Demand deposit	$	5,404	$	-	$	-	$	5,404
	Corporate debt securities		64,867		59		-4		64,922
	Government-sponsored enterprises		13,064		12		-		13,076
	U.S. Treasury notes		23,497		12		-		23,509
		$	106,832	$	83	$	-4	$	106,911
	December 31, 2012
	Demand deposit		5,641	$	—	$	—	$	5,641
	Corporate debt securities		104,652		91		-17		104,726
	Government-sponsored enterprises		33,438		18		—		33,456
	U.S. Treasury notes		97,563		57		-2		97,618
		$	241,294	$	166	$	-19	$	241,441

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Measurements [Abstract]	'
Schedule Of Financial Assets Measured At Fair Value On A Recurring Basis	'
	Description	Balance		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)
	Assets:	(In thousands)
	December 31, 2013
	Money market	$	68,534	$	68,534	$	—
	Commercial paper		6,000				6,000
	Corporate debt securities		64,922		—		64,922
	Government-sponsored enterprises		13,076		—		13,076
	U.S. Treasury notes		23,509		—		23,509
	Total financial assets		176,041	$	68,534	$	107,507
	Add: Cash		23,400
	Total cash, cash equivalents and investments	$	199,441
	December 31, 2012
	Money market	$	184,167	$	184,167	$	—
	Corporate debt securities		104,726		—		104,726
	Government-sponsored enterprises		33,456		—		33,456
	U.S. Treasury notes		97,618		—		97,618
	Total financial assets		419,967	$	184,167	$	235,800
	Add: Cash		9,882
	Total cash, cash equivalents and investments	$	429,849

Property_And_Equipment_Tables

Property And Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property And Equipment [Abstract]	'
Schedule Of Components Of Property And Equipment	'
		December 31,
		2013		2012
		(In thousands)
	Furniture and office equipment	$	2,823	$	2,111
	Laboratory and manufacturing equipment		29,493		29,590
	Computer equipment and software		70,976		66,117
	Leasehold improvements		117,233		115,735
	Buildings		17,872		17,872
	Construction in progress		368		2,313
			238,765		233,738
	Less accumulated depreciation and amortization		-113,597		-83,134
		$	125,168	$	150,604
Schedule Of Asset Retirement Obligations	'
		Year ended December 31,
		2013		2012
		(In thousands)
	Beginning balance, January 1	$	5,081	$	7,019
	Accretion		305		529
	Release related to sale of facility		-		-2,467
	Ending balance , December 31	$	5,386	$	5,081

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2013
Accrued Liabilities [Abstract]	'
Schedule Of Components Of Accrued Liabilities	'
		December 31,
		2013		2012
		(In thousands)
	Deferred rent	$	6,886	$	7,875
	Inventory receipts		1,551		6,636
	Accrued consulting and other services		7,313		12,016
	Accrued clinical trials expense		3,157		2,299
	Accrued interest		8,225		8,234
	Accrued service fees and rebates		2,899		3,533
	Other accrued liabilities		3,588		4,228
		$	33,619	$	44,821

Financing_Obligations_Tables

Financing Obligations (Tables)	12 Months Ended
	Dec. 31, 2013
Financing Obligations [Abstract]	'
Future Minimum Payments Due Under Capital Lease And Financing Obligations	'
		Capital Lease Obligations		Facility Lease Obligations
			(In thousands)
	Year ending December 31:
	2014	$	2,743	$	866
	2015		2,782		999
	2016		985		1,040
	2017		—		1,058
	2018		—		1,077
	Thereafter		—		7,365
	Total payments		6,510		12,405
	Less amount representing interest		-506		-1,650
	Present value of payments		6,004		10,755
	Less current portion of obligations		-2,429		-632
		$	3,575	$	10,123

Convertible_Notes_Tables

Convertible Notes (Tables)	12 Months Ended
	Dec. 31, 2013
Convertible Notes [Abstract]	'
Schedule Of Carrying Amount Of Liability Component And Remaining Unamortized Discount	'
		December 31,
		2013		2012
		(In thousands)
	Aggregate principal amount of 2016 Notes	$	620,000	$	620,000
	Unamortized discount of the liability component		60,878		87,256
	Carrying amount of the liability component	$	559,122	$	532,744

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2013
Stock-Based Compensation [Abstract]	'
Schedule Of Components Of Stock Compensation Expense	'
		Year Ended December 31,
		2013			2012		2011
		(in millions)
	Cost of product revenue	$	155		$	6,571	$	5,660
	Research and development		3,890			7,103		7,278
	Selling, general and administrative		9,940			55,984		42,301
	Restructuring		184			2,015		5,022
		$	14,169		$	71,673	$	60,261
Schedule Of Weighted Average Assumptions For Employee Stock Options And ESPP	'
		Employee Stock Options							Employee Stock Purchase Plan
		2013			2012		2011		2013		2012		2011
	Weighted average estimated	$	2.95		$	5.85	$	18.42	$	3.78	$	2.23	$	12.40
	fair value per share
	Weighted Average Assumptions
	Dividend yield (a)		0.0%			0.0%		0.0%		0.0%		0.0%		0.0%
	Expected volatility (b)		85%			76%		78%		70%		41%		45%
	Risk-free interest rate (c)		1.0%			0.9%		1.9%		0.3%		0.1%		0.0%
	Expected term (d)		5.0 years			5.2 years		5.0 years		1.7 years		0.9 years		1.1 years
		(a)		We have not paid dividends in the past and do not plan to pay dividends in the near future.
		(b)		The expected stock price volatility is based on the weighted average historical volatility of our stock.
		(c)		The risk-free interest rate is based on the implied yield available on United States Treasury zero-coupon issues with a term equal to the expected life of the award on the date of grant.
	(d)The expected term of options granted represents the estimated period of time until exercise and is based on the historical weighted average term of similar awards, giving consideration to the contractual terms, vesting schedules, expectations of future employee behavior and the terms of certain peer companies.
Summary Of Stock Option Activity	'
			2013					2012				2011
			Shares Under Option		Weighted-Average Exercise Price			Shares Under Option	Weighted-Average Exercise Price			Shares Under Option	Weighted-Average Exercise Price
	Outstanding at January 1		3,757,704		$	18.71		2,576,079	$	25.98		2,672,972	$	23.78
	Granted		367,722			6.13		1,838,520		10.11		805,469		29.51
	Exercised		-8,256			4.98		-49,551		5.03		-475,225		12.90
	Forfeited and expired		-1,108,277			25.01		-607,344		22.65		-427,137		33.42
	Outstanding at December 31		3,008,893			15.10		3,757,704		18.71		2,576,079		25.98
	Options exercisable at December 31		1,768,392			18.62		1,707,659		24.18		1,158,475		20.10
	Shares available for future grant		6,507,055					9,630,340				7,966,724
Summary Of Restricted Stock Award Activity	'
			2013					2012				2011
			Number of Shares		Weighted-Average Grant Date Fair Value			Number of Shares	Weighted-Average Grant Date Fair Value			Number of Shares	Weighted-Average Grant Date Fair Value
	Outstanding at January 1		4,217,355		$	13.87		1,963,711	$	26.22		2,214,260	$	23.85
	Granted		3,625,005			5.66		5,734,632		10.83		1,305,265		30.10
	Vested		-2,522,920			12.32		-2,462,846		16.60		-1,165,524		21.68
	Forfeited and expired		-1,399,468			11.47		-1,018,142		13.93		-390,290		28.48
	Outstanding at December 31		3,919,972			6.94		4,217,355		13.87		1,963,711		26.22
Equity Based Awards Available For Future Issuances	'
			Awards Available for Grant
	Balance at January 1, 2011		9,752,127
	Granted		-2,593,708
	Forfeited and expired		808,305
	Balance at December 31, 2011		7,966,724
	Additional shares reserved - 2009 Plan		9,000,000
	Additional shares reserved - 2012 Plan		3,000,000
	Granted		-9,748,353
	Forfeited and expired		1,838,580
	Cancelled - 2012 Plan		-2,426,611
	Balance at December 31, 2012		9,630,340
	Granted		-5,834,279
	Forfeited and expired		2,710,994
	Balance at December 31, 2013		6,507,055
Common Stock Reserved For Future Issuance	'
	Convertible senior subordinated notes due 2014		2,692,765
	Convertible senior notes due 2016		12,099,920
	Outstanding common stock options		3,008,893
	Employee stock purchase plan		9,517,000
	Common stock awards		3,919,972
	Available for future grant under equity plans		6,507,055
			37,745,605

Restructuring_Contract_Termina1

Restructuring, Contract Termination And Asset Impairment (Tables)	12 Months Ended
	Dec. 31, 2013
Restructuring, Contract Termination And Asset Impairment [Abstract]	'
Rollforward Of Restructuring Liabilities	'
	Description	Restructuring and Contract Termination Liabilities as of December 31, 2012		Charges, Net of Adjustments		Payments		Other Non-Cash Settlement		Restructuring and Contract Termination Liabilities as of December 31, 2013
		(In thousands)
	2013 Restructuring:
	Severance and other termination benefits	$	—	$	7,142	$	-2,605	$	-175	$	4,362
	Other associated costs		—		1,791		-1,502		—		289
	2012 Restructuring:
	Severance and other termination benefits		10,083		20		-10,094		-9		—
	Other associated costs		108		1,677		-1,643		—		142
	Asset impairment		—		-109		—		109		—
	2011 Restructuring:
	Contract termination costs		4,023		-2		-21		—		4,000
	Total	$	14,214	$	10,519	$	-15,865	$	-75	$	8,793

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Taxes [Abstract]	'
Components Of Deferred Tax Assets And Liabilities	'
		December 31,
		2013		2012
		(In thousands)
	Deferred tax assets:
	Net operating loss carryforwards	$	591,145	$	521,171
	R&D credit carryforwards		28,622		27,239
	Stock-based compensation		10,188		21,239
	Fixed assets		3,838		1,157
	Other		40,383		24,716
	Total deferred tax assets	$	674,176	$	595,522
	Valuation allowance		-651,164		-562,723
	Net deferred tax assets		23,012		32,799
	Deferred tax liabilities:
	Convertible debt obligation		-23,012		-32,799
	Net deferred tax assets and liabilities	$	—	$	—
Schedule Of Unrecognized Tax Benefits	'
			Year ended December 31,
		2013		2012		2011
			(In thousands)
	Balance at January 1	$	6,380	$	4,915	$	4,401
	Additions for tax positions related to current year		—		—		—
	Additions/reductions for tax positions of prior years		-2,309		1,465		514
	Settlements		—		—		—
	Balance at December 31	$	4,071	$	6,380	$	4,915

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2013
Net Loss Per Share [Abstract]	'
Calculation Of Basic And Diluted Net Loss Per Share	'
		December 31,
		2013		2012		2011
		(In thousands, except per share amounts)
	Net loss	$	-296,804	$	-393,610	$	-337,806
	Weighted average shares used in computation of basic and diluted net loss per share		151,985		148,777		146,163
	Basic and diluted net loss per share	$	-1.95	$	-2.65	$	-2.31

Commitments_And_Contingencies_

Commitments And Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies [Abstract]	'
Schedule Of Future Minimum Lease Payments	'
		Operating Leases
		(In thousands)
	Year ending December 31:
	2014	$	9,192
	2015		8,859
	2016		8,920
	2017		5,989
	2018		6,166
	Thereafter		8,266
	Total minimum lease payments	$	47,392

Quarterly_Information_Tables

Quarterly Information (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Information [Abstract]	'
Summary Of Unaudited Statements Of Operations	'
		31-Mar			30-Jun		30-Sep		31-Dec
	2013	(In thousands, except per share amounts)
	Total revenue	$	67,594		$	73,315	$	68,002	$	74,835
	Cost of product revenue (3)		43,375			43,798		40,679		38,476
	Loss on inventory impairment (4)		—			—		6,254		39,992
	Gross profit (2)		24,205			29,488		21,049		-3,640
	Restructuring, contract termination and asset impairment expense		1,960			-304		1,188		7,675
	Net loss		-72,005			-68,842		-67,215		-88,742
	Basic and diluted net loss per share	$	-0.48		$	-0.45	$	-0.44	$	-0.58
		31-Mar			30-Jun		30-Sep		31-Dec
	2012	(In thousands, except per share amounts)
	Total revenue (1)	$	82,074		$	79,992	$	77,971	$	85,493
	Cost of product revenue		60,041			61,731		51,749		54,371
	Gross profit (2)		21,931			18,233		26,193		31,084
	Restructuring, contract termination and asset impairment expense (5)		-124			1,099		80,994		-36,302
	Net loss		-103,914			-96,137		-154,864		-38,695
	Basic and diluted net loss per share	$	-0.7		$	-0.65	$	-1.04	$	-0.26
		-1		Total revenue for the quarter ended December 31, 2012 includes a $3.8 million favorable change in estimate related to PHS chargebacks. See Note 2 – Significant Accounting Policies – Revenue Recognition.
		-2		Gross profit is calculated by subtracting cost of product revenue (including loss on inventory impairment) from product revenue.
		-3		Cost of product revenue for the quarter ended September 30, 2013 has been adjusted to exclude $6.3 million in loss on inventory impairment, which is now separately disclosed as “Loss on inventory impairment” on the consolidated statements of operations.
		-4		See Note 5 – Inventory for details of losses on inventory impairment recorded in the third and fourth quarters of 2013.
		-5		Restructuring, contract termination and asset impairment expense for the quarter ended September 30, 2012 includes impairment charges of $65.3 million related to our decision to close the New Jersey Facility and the discontinued development of a non-essential computer software project. Upon sale of the New Jersey Facility to Novartis in December 2012, restructuring, contract termination and asset impairment expense for the quarter ended December 31, 2012 includes the recovery of $47.4 million. The recovery was calculated as the proceeds from the sale of the facility of $43.0 million, plus the release of the facility-specific lease and asset retirement obligations, less the remaining net book value of the New Jersey Facility. Refer to Note 13 – Restructuring, Contract Termination and Asset Impairment.

Significant_Accounting_Policie3

Significant Accounting Policies (Narrative) (Details) (USD $)	3 Months Ended	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Product usable life	'	'18 hours	'	'
Royalty revenue	'	'	'	$3
Revenue from sale of royalty stream	125	'	'	'
Zero cost inventory usage	'	'	4.7	18.4
Estimated remaining life of raw material inventory	'	'3 years	'	'
Remaining estimated useful life of long-lived assets	'	'7 years	'	'
Cumulative catch-up adjustment to reduce stock-based compensation expense	'	$7.50	'	'
Decrease to net loss per share	'	$0.05	'	'
Laboratory And Manufacturing Equipment [Member]	'	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Remaining estimated useful life of long-lived assets	'	'7 years	'	'
Furniture And Office Equipment [Member]	'	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Remaining estimated useful life of long-lived assets	'	'7 years	'	'
Computers And Software [Member]	'	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Remaining estimated useful life of long-lived assets	'	'3 years	'	'
Leasehold Improvements [Member]	'	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Remaining estimated useful life of long-lived assets	'	'10 years	'	'
Convertible Senior Notes Due 2014 [Member]	'	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Interest rate of debt	'	4.75%	'	'
Debt instrument maturity year	'	'2014	'	'
Convertible Senior Notes Due 2016 [Member]	'	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Interest rate of debt	'	2.88%	'	'
Convertible senior notes conversion ratio	'	0.019516	'	'
Convertible senior notes initial conversion price	'	$51.24	'	'
Debt instrument maturity year	'	'2016	'	'
Effective interest rate at issuance date	'	8.10%	'	'
Stock Appreciation Rights [Member]	'	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Vesting period	'	'2 years	'	'
Minimum [Member] | Buildings [Member]	'	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Remaining estimated useful life of long-lived assets	'	'14 years	'	'
Minimum [Member] | Restricted Stock [Member]	'	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Vesting period	'	'2 years	'	'
Maximum [Member] | Buildings [Member]	'	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Remaining estimated useful life of long-lived assets	'	'15 years	'	'
Maximum [Member] | Restricted Stock [Member]	'	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Vesting period	'	'4 years	'	'

Significant_Accounting_Policie4

Significant Accounting Policies (Schedule Of Chargebacks Reserve) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
PSS And FSS Customers [Member]	'	'
Revenue, Major Customer [Line Items]	'	'
Beginning balance, January 1	$3,107	$7,065
Current provision related to sales made in current period	15,070	16,615
Current provision related to sales made in prior periods	'	50
Adjustments	-2,775	-3,824
Payments/credits	-11,862	-16,799
Balance at December 31	3,540	3,107
Certain GPOs [Member]	'	'
Revenue, Major Customer [Line Items]	'	'
Beginning balance, January 1	182	'
Current provision related to sales made in current period	11,031	779
Payments/credits	-9,623	-597
Balance at December 31	$1,590	$182

Significant_Accounting_Policie5

Significant Accounting Policies (Schedule Of Estimated And Accrued Rebates and Administrative Fees) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Significant Accounting Policies [Abstract]	'	'
Beginning balance, January 1	$1,950	$885
Current provision related to sales made in current period	6,459	7,600
Current provision related to sales made in prior periods	'	57
Payments/credits	-6,621	-6,592
Ending balnace, December 31	$1,788	$1,950

Investments_Narrative_Details

Investments (Narrative) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Investments [Abstract]	'	'
Investments securing letters of credit	$5.40	$5.60

Investments_Schedule_Of_Availa

Investments (Schedule Of Available-For-Sale Securities) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Investments [Abstract]	'	'
Due in one year or less, Cost or Amortized Cost	$87,027	$165,295
Due after one year through two years, Cost or Amortized Cost	19,805	75,999
Total debt securities available for sale, Cost or Amortized Cost	106,832	241,294
Due in one year or less, Fair Market Value	87,092	165,396
Due after one year through two years, Fair Market Value	19,819	76,045
Total debt securities available for sale, Fair Market Value	$106,911	$241,441

Investments_Schedule_Of_ShortT

Investments (Schedule Of Short-Term And Long-Term Securities Available-For-Sale) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost or Amortized Cost	$106,832	$241,294
Gross Unrealized Gains	83	166
Gross Unrealized Losses	-4	-19
Total debt securities available for sale	106,911	241,441
Demand Deposit [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost or Amortized Cost	5,404	5,641
Total debt securities available for sale	5,404	5,641
Corporate Debt Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost or Amortized Cost	64,867	104,652
Gross Unrealized Gains	59	91
Gross Unrealized Losses	-4	-17
Total debt securities available for sale	64,922	104,726
Government-Sponsored Enterprises [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost or Amortized Cost	13,064	33,438
Gross Unrealized Gains	12	18
Total debt securities available for sale	13,076	33,456
U.S. Treasury Notes [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost or Amortized Cost	23,497	97,563
Gross Unrealized Gains	12	57
Gross Unrealized Losses	'	-2
Total debt securities available for sale	$23,509	$97,618

Fair_Value_Measurements_Narrat

Fair Value Measurements (Narrative) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Convertible Senior Notes Due 2016 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Fair value of convertible notes	$393.80	$471.20
Convertible Senior Notes Due 2014 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Fair value of convertible notes	$27.30	$25.30

Fair_Value_Measurements_Schedu

Fair Value Measurements (Schedule Of Financial Assets Measured At Fair Value On A Recurring Basis) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	$176,041	$419,967
Add: Cash	23,400	9,882
Total cash, cash equivalents and investments	199,441	429,849
Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	68,534	184,167
Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	107,507	235,800
Money Market [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	68,534	184,167
Money Market [Member] | Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	68,534	184,167
Money Market [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	'	'
Commercial Paper [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	6,000	'
Commercial Paper [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	6,000	'
Corporate Debt Securities [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	64,922	104,726
Corporate Debt Securities [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	64,922	104,726
Government-Sponsored Enterprises [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	13,076	33,456
Government-Sponsored Enterprises [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	13,076	33,456
U.S. Treasury Notes [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	23,509	97,618
U.S. Treasury Notes [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	$23,509	$97,618

Inventory_Details

Inventory (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Inventory [Abstract]	'	'
Raw materials	$54.30	$76.30
Inventory impairment insurance coverage, amount	30	'
Expense related to antigen inventory not useable for commercial production	$46.20	'

Prepaid_Expenses_And_Other_Cur1

Prepaid Expenses And Other Current Assets (Details) (Prepaid Expenses And Other Current Assets [Member], USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Prepaid Expenses And Other Current Assets [Member]	'	'
Costs associated with agreements to develop second source suppliers for materials and to qualify a contract manufacturer for production	$5.90	$8.50

Property_And_Equipment_Narrati

Property And Equipment (Narrative) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
				Atlanta Facility [Member]
Property, Plant and Equipment [Line Items]	'	'	'	'
Cost of title transferred assets	'	'	'	$63.30
Depreciation expense	30.8	39.7	36.7	'
Capitalized interest	$0	$0.30	$1.20	'

Property_And_Equipment_Schedul

Property And Equipment (Schedule Of Components Of Property And Equipment) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	$238,765	$233,738
Less accumulated depreciation and amortization	-113,597	-83,134
Property and equipment, net	125,168	150,604
Furniture And Office Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	2,823	2,111
Laboratory And Manufacturing Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	29,493	29,590
Computer Equipment And Software [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	70,976	66,117
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	117,233	115,735
Buildings [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	17,872	17,872
Construction In Progress [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	$368	$2,313

Property_And_Equipment_Schedul1

Property And Equipment (Schedule Of Asset Retirement Obligations) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Property And Equipment [Abstract]	'	'
Beginning balance, January 1	$5,081	$7,019
Accretion	305	529
Release related to sale of facility	'	-2,467
Ending balance	$5,386	$5,081

Accrued_Liabilities_Schedule_O

Accrued Liabilities (Schedule Of Components Of Accrued Liabilities) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accrued Liabilities [Abstract]	'	'
Deferred rent	$6,886	$7,875
Inventory receipts	1,551	6,636
Accrued consulting and other services	7,313	12,016
Accrued clinical trials expense	3,157	2,299
Accrued interest	8,225	8,234
Accrued service fees and rebates	2,899	3,533
Other accrued liabilities	3,588	4,228
Accrued liabilities	$33,619	$44,821

Financing_Obligations_Details

Financing Obligations (Details) (USD $)	12 Months Ended		12 Months Ended			12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Aug. 31, 2009	Dec. 31, 2013	Mar. 31, 2010	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
	Orange County Facility [Member]	Orange County Facility [Member]	Atlanta Facility [Member]	Atlanta Facility [Member]	Software Licenses And Equipment [Member]	Software Licenses And Equipment [Member]	Software Licenses And Equipment [Member]
						Minimum [Member]	Maximum [Member]
Capital Leased Assets [Line Items]	'	'	'	'	'	'	'
Amount capitalized related to fair value of building owned	'	$6.70	'	$6.40	'	'	'
Extended term of lease, years	'15 years 6 months	'	'15 years 6 months	'	'	'	'
Effective interest rate of facility leases	1.46%	'	3.37%	'	'	'	'
Initial term of lease, years	'10 years 6 months	'	'10 years 6 months	'	'	'	'
Extension period of lease renewal term	'5 years	'	'5 years	'	'	'	'
Estimated term of facility lease	'15 years 6 months	'	'15 years 6 months	'	'	'	'
Additional renewal term, years	'20 years	'	'20 years	'	'	'	'
Aggregate remaining obligation of facility leases	5.3	'	5.5	'	'	'	'
Aggregate remaining obligation of capital leases	'	'	'	'	$6	'	'
Annual interest rate of capital leases	'	'	'	'	'	4.40%	11.70%

Financing_Obligations_Schedule

Financing Obligations (Schedule Of Future Minimum Lease Payments Due Under Capital Lease And Financing Obligations) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'
Capital Lease Obligations, Less current portion of obligations	($2,429)	($4,418)
Capital Lease Obligations, Noncurrent portion of obligations	3,575	6,219
Facility Lease Obligations, Less current portion of obligations	-632	-594
Facility Lease Obligations, Noncurrent portion of obligations	10,123	10,835
Capital Lease Obligations [Member]	'	'
Debt Instrument [Line Items]	'	'
Lease Obligations, 2014	2,743	'
Lease Obligations, 2015	2,782	'
Lease Obligations, 2016	985	'
Lease Obligations, Total payments	6,510	'
Lease Obligations, Amount representing interest	-506	'
Lease Obligations, Present value of payments	6,004	'
Capital Lease Obligations, Less current portion of obligations	-2,429	'
Capital Lease Obligations, Noncurrent portion of obligations	3,575	'
Facility Lease Obligations [Member]	'	'
Debt Instrument [Line Items]	'	'
Lease Obligations, 2014	866	'
Lease Obligations, 2015	999	'
Lease Obligations, 2016	1,040	'
Lease Obligations, 2017	1,058	'
Lease Obligations, 2018	1,077	'
Lease Obligations, Thereafter	7,365	'
Lease Obligations, Total payments	12,405	'
Lease Obligations, Amount representing interest	-1,650	'
Lease Obligations, Present value of payments	10,755	'
Facility Lease Obligations, Less current portion of obligations	-632	'
Facility Lease Obligations, Noncurrent portion of obligations	$10,123	'

Convertible_Notes_2016_Notes_D

Convertible Notes (2016 Notes) (Details) (USD $)	0 Months Ended		12 Months Ended
	Feb. 03, 2011	Jan. 20, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Debt Instrument [Line Items]	'	'	'	'	'
Face amount of notes issued	'	'	$620,000,000	$620,000,000	'
Proceeds from issuance of convertible senior notes	'	'	'	'	607,129,000
Convertible Senior Notes Due 2016 [Member]	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'
Face amount of notes issued	80,000,000	540,000,000	'	'	'
Debt instrument maturity year	'	'	'2016	'	'
Proceeds from issuance of convertible senior notes	78,300,000	528,800,000	'	'	'
Convertible senior notes initial conversion price	'	'	$51.24	'	'
Minimum number of days conversion rate increase must last	'	'	'20 days	'	'
Number of days written notice that is required prior to a conversion rate increase	'	'	'15 days	'	'
Convertible senior notes conversion ratio	'	'	0.019516	'	'
Debt instrument effective interest rate	'	'	8.10%	'	'
Interest rate of debt	'	'	2.88%	'	'
Payments of debt issuance costs	'	'	12,900,000	'	'
Carrying amount of the equity component	'	'	132,900,000	'	'
Convertible senior notes repurchase price	'	'	100.00%	'	'
Non-cash interest expense on debt discount and debt issuance costs	'	'	28,400,000	26,200,000	23,000,000
Interest on convertible senior notes based on stated coupon rate	'	'	17,800,000	17,800,000	16,800,000
Convertible Senior Notes Due 2016 [Member] | Equity Component [Member]	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'
Payments of debt issuance costs	'	'	2,800,000	'	'
Convertible Senior Notes Due 2016 [Member] | Liability Component [Member]	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'
Payments of debt issuance costs	'	'	$10,100,000	'	'
Maximum [Member] | Convertible Senior Notes Due 2016 [Member]	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'
Convertible senior notes conversion ratio	'	'	0.0273224	'	'

Convertible_Notes_2014_Notes_D

Convertible Notes (2014 Notes) (Details) (USD $)	1 Months Ended	12 Months Ended
	Jul. 31, 2007	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Debt Instrument [Line Items]	'	'	'	'
Face amount of notes issued	'	$620,000,000	$620,000,000	'
Proceeds from issuance of convertible senior notes	'	'	'	607,129,000
Current portion of convertible debt	'	27,685,000	'	'
Aggregate convertible notes principal amount outstanding	'	'	27,685,000	'
Convertible Senior Notes Due 2014 [Member]	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'
Face amount of notes issued	85,300,000	'	'	'
Payments of debt issuance costs	3,000,000	'	'	'
Proceeds from issuance of convertible senior notes	82,300,000	'	'	'
Interest rate of debt	4.75%	'	'	'
Debt instrument maturity year	'	'2014	'	'
Additional interest rate percentage	'	1.00%	'	'
Convertible senior notes initial conversion price	'	$10.28	'	'
Convertible senior notes conversion ratio	'	0.0972644	'	'
Convertible senior notes repurchase price	'	100.00%	'	'
Minimum number of days conversion rate increase must last	'	'20 days	'	'
Number of days written notice that is required prior to a conversion rate increase	'	'15 days	'	'
Current portion of convertible debt	'	27,700,000	'	'
Interest on convertible senior notes based on stated coupon rate	'	$1,500,000	$1,500,000	$1,500,000
Maximum [Member] | Convertible Senior Notes Due 2014 [Member]	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'
Convertible senior notes conversion ratio	'	0.1142857	'	'

Convertible_Notes_Schedule_Of_

Convertible Notes (Schedule Of Carrying Amount Of Liability Component And Remaining Unamortized Discount) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Convertible Notes [Abstract]	'	'
Aggregate principal amount of 2016 Notes	$620,000	$620,000
Unamortized discount of the liability component	60,878	87,256
Carrying amount of the liability component	$559,122	$532,744

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Stockholders' Equity [Line Items]	'	'
Preferred stock authorized	10,000,000	10,000,000
Preferred stock par value	$0.00	$0.00
Preferred stock issued	0	0
Preferred stock outstanding	0	0
Series A Preferred Stock [Member]	'	'
Stockholders' Equity [Line Items]	'	'
Preferred stock authorized	2,500,000	2,500,000

StockBased_Compensation_Narrat

Stock-Based Compensation (Narrative) (Details) (USD $)

12 Months Ended

12 Months Ended

In Millions, except Share data, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Mar. 31, 2012

Jan. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

2000 Plan [Member]

2002 Plan [Member]

2009 Plan [Member]

2009 Plan [Member]

2012 Plan [Member]

2013 Plan [Member]

2013 Plan [Member]

2013 Plan [Member]

Minimum [Member]

Maximum [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Stock Options [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Cash-Settled Stock Appreciation Rights [Member]

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Stock Options [Member]

Stock Options [Member]

Minimum [Member]

Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase in net loss per share related to stock compensation expense

$0.09

$0.48

$0.41

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vesting period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'4 years

'

'2 years

'4 years

'

'

'

'

'2 years

Minimum percentage of fair value for option price of stock options

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares authorized and reserved for issuance

'

'

'

10,000,000

'

'

'

'

22,200,000

13,200,000

3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options expiration period

'

'

'

'

'

'

'10 years

'10 years

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock award share ratio

'

'

'

'

'

'

'

'

1.37

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued under ESPP

'

'

'

500,000

700,000

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average prices of shares issued

'

'

'

'

'

'

'

'

'

'

'

$3.18

$5.57

$14.16

'

'

'

'

'

'

'

'

'

'

Stock compensation expense

$14,169

$71,673

$60,261

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.10

$0.20

$1.60

$0.20

Weighted-average remaining contractual term for options outstanding, years

'6 years 10 months 24 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted-average remaining contractual term for options exercisable, years

'5 years 9 months 18 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average period over which unrecognized compensation is expected to be recognized related to stock options

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 year 1 month 6 days

'

'

'1 year 2 months 12 days

'

'

'

'1 year 4 months 24 days

Aggregate intrinsic value of options exercised

'

0.2

9.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total fair value of the options vested

3.3

7.1

8.7

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of stock awards vested

12.3

19.5

32.1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized stock compensation expense related to unvested restricted stock awards

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$8.60

'

'

$1.90

'

'

'

$0.40

StockBased_Compensation_Schedu

Stock-Based Compensation (Schedule Of Components Of Stock Compensation Expense) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock compensation expense	$14,169	$71,673	$60,261
Cost Of Product Revenue [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock compensation expense	155	6,571	5,660
Research And Development [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock compensation expense	3,890	7,103	7,278
Selling, General And Administrative [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock compensation expense	9,940	55,984	42,301
Restructuring [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock compensation expense	$184	$2,015	$5,022

StockBased_Compensation_Schedu1

Stock-Based Compensation (Schedule Of Weighted Average Assumptions For Employee Stock Options) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Stock Options [Member]	'		'		'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'		'		'
Weighted average estimated fair value per share	$2.95		$5.85		$18.42
Dividend yield	0.00%	[1]	0.00%	[1]	0.00%	[1]
Expected volatility	85.00%	[2]	76.00%	[2]	78.00%	[2]
Risk-free interest rate	1.00%	[1],[3]	0.90%	[1],[3]	1.90%	[1],[3]
Expected term (in years)	'5 years	[2],[4]	'5 years 2 months 12 days	[2],[4]	'5 years	[2],[4]
Employee Stock Purchase Plan [Member]	'		'		'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'		'		'
Weighted average estimated fair value per share	$3.78		$2.23		$12.40
Dividend yield	0.00%	[1]	0.00%	[1]	0.00%	[1]
Expected volatility	70.00%	[2]	41.00%	[2]	45.00%	[2]
Risk-free interest rate	0.30%	[1],[3]	0.10%	[1],[3]	0.00%	[1],[3]
Expected term (in years)	'1 year 8 months 12 days	[2],[4]	'10 months 24 days	[2],[4]	'1 year 1 month 6 days	[2],[4]
[1]	We have not paid dividends in the past and do not plan to pay dividends in the near future.
[2]	The expected stock price volatility is based on the weighted average historical volatility of our stock.
[3]	The risk-free interest rate is based on the implied yield available on United States Treasury zero-coupon issues with a term equal to the expected life of the award on the date of grant.
[4]	The expected term of options granted represents the estimated period of time until exercise and is based on the historical weighted average term of similar awards, giving consideration to the contractual terms, vesting schedules, expectations of future employee behavior and the terms of certain peer companies

StockBased_Compensation_Summar

Stock-Based Compensation (Summary Of Stock Option Activity) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stock-Based Compensation [Abstract]	'	'	'
Outstanding at January 1	3,757,704	2,576,079	2,672,972
Granted	367,722	1,838,520	805,469
Exercised	-8,256	-49,551	-475,225
Forfeited and expired	-1,108,277	-607,344	-427,137
Outstanding at December 31	3,008,893	3,757,704	2,576,079
Options exercisable at December 31	1,768,392	1,707,659	1,158,475
Weighted-Average Exercise Price per Share, Outstanding at January 1	$18.71	$25.98	$23.78
Weighted-Average Exercise Price per Share, Granted	$6.13	$10.11	$29.51
Weighted-Average Exercise Price per Share, Exercised	$4.98	$5.03	$12.90
Weighted-Average Exercise Price per Share, Forfeited and expired	$25.01	$22.65	$33.42
Weighted-Average Exercise Price per Share, Outstanding at December 31	$15.10	$18.71	$25.98
Weighted-Average Exercise Price per Share, Options exercisable at December 31	$18.62	$24.18	$20.10
Shares avaliable for future grant	6,507,055	9,630,340	7,966,724

StockBased_Compensation_Summar1

Stock-Based Compensation (Summary Of Restricted Stock Award) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stock-Based Compensation [Abstract]	'	'	'
Outstanding at January 1	4,217,355	1,963,711	2,214,260
Granted	3,625,005	5,734,632	1,305,265
Vested	-2,522,920	-2,462,846	-1,165,524
Forfeited and expired	-1,399,468	-1,018,142	-390,290
Outstanding at December 31	3,919,972	4,217,355	1,963,711
Weighted-Average Grant Date Fair Value, Outstanding at January 1	$13.87	$26.22	$23.85
Weighted-Average Grant Date Fair Value, Granted	$5.66	$10.83	$30.10
Weighted-Average Grant Date Fair Value, Vested	$12.32	$16.60	$21.68
Weighted-Average Grant Date Fair Value, Forfeited and expired	$11.47	$13.93	$28.48
Weighted-Average Grant Date Fair Value, Outstanding at December 31	$6.94	$13.87	$26.22

StockBased_Compensation_Plans_

Stock-Based Compensation Plans (Equity Based Awards Available For Future Issuances) (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Beginning Balance	9,630,340	7,966,724	'
Granted	-367,722	-1,838,520	-805,469
Forfeited and expired	1,108,277	607,344	427,137
Ending Balance	6,507,055	9,630,340	7,966,724
Restricted Stock And Stock Options [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Beginning Balance	9,630,340	7,966,724	9,752,127
Granted	-5,834,279	-9,748,353	-2,593,708
Forfeited and expired	2,710,994	1,838,580	808,305
Ending Balance	6,507,055	9,630,340	7,966,724
2009 Plan [Member] | Restricted Stock And Stock Options [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Additional shares reserved	'	9,000,000	'
2012 Plan [Member] | Restricted Stock And Stock Options [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Additional shares reserved	'	3,000,000	'
Cancelled	'	-2,426,611	'

StockBased_Compensation_Common

Stock-Based Compensation (Common Stock Reserved For Future Issuance) (Details)	Dec. 31, 2013
Class of Stock [Line Items]	'
Common stock reserved for issuance	37,745,605
Convertible Senior Notes Due 2014 [Member]	'
Class of Stock [Line Items]	'
Common stock reserved for issuance	2,692,765
Convertible Senior Notes Due 2016 [Member]	'
Class of Stock [Line Items]	'
Common stock reserved for issuance	12,099,920
Outstanding Common Stock Options [Member]	'
Class of Stock [Line Items]	'
Common stock reserved for issuance	3,008,893
Employee Stock Purchase Plan [Member]	'
Class of Stock [Line Items]	'
Common stock reserved for issuance	9,517,000
Common Stock Awards [Member]	'
Class of Stock [Line Items]	'
Common stock reserved for issuance	3,919,972
Available For Future Grant Under Equity Plans [Member]	'
Class of Stock [Line Items]	'
Common stock reserved for issuance	6,507,055

Restructuring_Contract_Termina2

Restructuring, Contract Termination And Asset Impairment (Narrative) (Details) (USD $)

0 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Jul. 30, 2012

Sep. 02, 2011

Dec. 31, 2012

Sep. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2014

Sep. 30, 2012

Sep. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

employee

employee

Novartis [Member]

Workforce [Member]

Agreement With GSK [Member]

Other Termination Benefits [Member]

Severance And Other Related Benefits [Member]

Severance And Other Related Benefits [Member]

Other Associated Costs [Member]

Other Associated Costs [Member]

Scenario, Forecast [Member]

Facility Closure [Member]

Software Project [Member]

2013 Restructuring [Member]

New Jersey Facility [Member]

New Jersey Facility [Member]

New Jersey Facility [Member]

employee

Software Project [Member]

Restructuring Cost and Reserve [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reduction in workforce

600

500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of eliminated employees who were offerred positions with buyer of facility

'

'

'

'

'

'

100

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring, contract termination and asset impairment

'

'

'

'

$8,900,000

$27,900,000

'

'

$19,200,000

'

$7,100,000

$19,400,000

$1,700,000

$7,800,000

$400,000

$60,000,000

$5,300,000

$1,600,000

'

$12,600,000

'

Expected implementation period of restructuring initiatives

'

'

'

'

'6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Charge for severance and other related termination benefits

'

'

'

'

1,400,000

20,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring expense reduction

'

'

'

'

'

'

'

-300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from sale of facility

'

'

43,000,000

'

'

43,000,000

43,000,000

'

'

'

'

'

'

'

'

'

'

'

43,000,000

'

'

Restructuring cost recovery

'

'

47,400,000

'

'

'

47,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Asset impairment related to restructuring and contract termination

'

'

'

65,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

17,900,000

Workforce rate

'

25.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring liability reduction

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

Cancellation fee under development and supply agreement

'

'

'

'

$4,000,000

'

'

'

$4,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring_Contract_Termina3

Restructuring, Contract Termination And Asset Impairment (Restructuring Charges And Contract Termination Liabilities) (Details) (USD $)

3 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Restructuring Cost and Reserve [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Restructuring and Contract Termination Liabilities as of December 31, 2012

'

'

'

$14,214

'

'

'

'

$14,214

'

'

Charges, Net Of Adjustments

7,675

1,188

-304

1,960

-36,302

[1]

80,994

[1]

1,099

[1]

-124

[1]

10,519

45,667

38,587

Payments

'

'

'

'

'

'

'

'

-15,865

'

'

Other Non-Cash Settlement

'

'

'

'

'

'

'

'

-75

'

'

Restructuring and Contract Termination Liabilities as of December 31,2013

8,793

'

'

'

14,214

'

'

'

8,793

14,214

'

2013 Restructuring [Member] | Severance And Other Termination Benefits [Member]

'

'

'

'

'

'

'

'

'

'

'

Restructuring Cost and Reserve [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Charges, Net Of Adjustments

'

'

'

'

'

'

'

'

7,142

'

'

Payments

'

'

'

'

'

'

'

'

-2,605

'

'

Other Non-Cash Settlement

'

'

'

'

'

'

'

'

-175

'

'

Restructuring and Contract Termination Liabilities as of December 31,2013

4,362

'

'

'

'

'

'

'

4,362

'

'

2013 Restructuring [Member] | Other Associated Costs [Member]

'

'

'

'

'

'

'

'

'

'

'

Restructuring Cost and Reserve [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Charges, Net Of Adjustments

'

'

'

'

'

'

'

'

1,791

'

'

Payments

'

'

'

'

'

'

'

'

-1,502

'

'

Restructuring and Contract Termination Liabilities as of December 31,2013

289

'

'

'

'

'

'

'

289

'

'

2012 Restructuring [Member] | Severance And Other Termination Benefits [Member]

'

'

'

'

'

'

'

'

'

'

'

Restructuring Cost and Reserve [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Restructuring and Contract Termination Liabilities as of December 31, 2012

'

'

'

10,083

'

'

'

'

10,083

'

'

Charges, Net Of Adjustments

'

'

'

'

'

'

'

'

20

'

'

Payments

'

'

'

'

'

'

'

'

-10,094

'

'

Other Non-Cash Settlement

'

'

'

'

'

'

'

'

-9

'

'

2012 Restructuring [Member] | Other Associated Costs [Member]

'

'

'

'

'

'

'

'

'

'

'

Restructuring Cost and Reserve [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Restructuring and Contract Termination Liabilities as of December 31, 2012

'

'

'

108

'

'

'

'

108

'

'

Charges, Net Of Adjustments

'

'

'

'

'

'

'

'

1,677

'

'

Payments

'

'

'

'

'

'

'

'

-1,643

'

'

Restructuring and Contract Termination Liabilities as of December 31,2013

142

'

'

'

'

'

'

'

142

'

'

2012 Restructuring [Member] | Asset Impairment [Member]

'

'

'

'

'

'

'

'

'

'

'

Restructuring Cost and Reserve [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Charges, Net Of Adjustments

'

'

'

'

'

'

'

'

-109

'

'

Other Non-Cash Settlement

'

'

'

'

'

'

'

'

109

'

'

2011 Restructuring [Member] | Contract Termination Costs [Member]

'

'

'

'

'

'

'

'

'

'

'

Restructuring Cost and Reserve [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Restructuring and Contract Termination Liabilities as of December 31, 2012

'

'

'

4,023

'

'

'

'

4,023

'

'

Charges, Net Of Adjustments

'

'

'

'

'

'

'

'

-2

'

'

Payments

'

'

'

'

'

'

'

'

-21

'

'

Restructuring and Contract Termination Liabilities as of December 31,2013

$4,000

'

'

'

'

'

'

'

$4,000

'

'

[1]

Restructuring, contract termination and asset impairment expense for the quarter ended SeptemberB 30, 2012 includes impairment charges of $65.3 million related to our decision to close the New Jersey Facility and the discontinued development of a non-essential computer software project. Upon sale of the New Jersey Facility to Novartis in December 2012, restructuring, contract termination and asset impairment expense for the quarter ended DecemberB 31, 2012 includes the recovery of $47.4 million. The recovery was calculated as the proceeds from the sale of the facility of $43.0 million, plus the release of the facility-specific lease and asset retirement obligations, less the remaining net book value of the New Jersey Facility. Refer to Note 13 - Restructuring, Contract Termination and Asset Impairment.

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Contingency [Line Items]	'	'	'
Income tax expense (benefit)	$0	$0	$0
Research and development credit carryforwards	28,622,000	27,239,000	'
Net operating loss related to excess tax benefits	156,300,000	156,300,000	'
R&D Credits	1,400,000	'	'
Increase in valuation allowance	88,400,000	143,100,000	66,100,000
Unrecognized tax benefits that if recognized would affect the annual effective tax rate	0	0	0
Federal [Member]	'	'	'
Income Tax Contingency [Line Items]	'	'	'
Research and development credit carryforwards	26,000,000	'	'
Net operating loss carryforwards	1,760,000,000	'	'
State [Member]	'	'	'
Income Tax Contingency [Line Items]	'	'	'
Research and development credit carryforwards	2,600,000	'	'
Net operating loss carryforwards	$541,100,000	'	'

Income_Taxes_Components_Of_Def

Income Taxes (Components Of Deferred Tax Assets And Liabilities) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Income Taxes [Abstract]	'	'
Net operating loss carryforwards	$591,145	$521,171
R&D credit carryforwards	28,622	27,239
Stock-based compensation	10,188	21,239
Fixed assets	3,838	1,157
Other	40,383	24,716
Total deferred tax assets	674,176	595,522
Valuation allowance	-651,164	-562,723
Net deferred tax assets	23,012	32,799
Convertible debt obligation	-23,012	-32,799
Net deferred tax assets and liabilities	'	'

Income_Taxes_Schedule_Of_Unrec

Income Taxes (Schedule Of Unrecognized Tax Benefits) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Taxes [Abstract]	'	'	'
Balance at January 1	$6,380	$4,915	$4,401
Additions for tax positions related to current year	'	'	'
Additions/reductions for tax positions of prior years	-2,309	1,465	514
Settlements	'	'	'
Balance at December 31	$4,071	$6,380	$4,915

Net_Loss_Per_Share_Calculation

Net Loss Per Share (Calculation Of Basic And Diluted Net Loss Per Share) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Net Loss Per Share [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Net loss	($88,742)	($67,215)	($68,842)	($72,005)	($38,695)	($154,864)	($96,137)	($103,914)	($296,804)	($393,610)	($337,806)
Weighted average shares used in computation of basic and diluted net loss per share	'	'	'	'	'	'	'	'	151,985,000	148,777,000	146,163,000
Basic and diluted net loss per share	($0.58)	($0.44)	($0.45)	($0.48)	($0.26)	($1.04)	($0.65)	($0.70)	($1.95)	($2.65)	($2.31)
Shares excluded from net loss per share	'	'	'	'	'	'	'	'	21,700,000	22,800,000	19,300,000

Commitments_And_Contingencies_1

Commitments And Contingencies (Details) (USD $)

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

In Millions, except Share data in Thousands, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Jul. 31, 2012

Feb. 28, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

plaintiff

FujiFilm [Member]

Bridgewater Space [Member]

Seattle Lease [Member]

Seattle Lease [Member]

Seattle Lease [Member]

Seattle Lease [Member]

Seattle Sublease [Member]

Orange County Facility [Member]

Orange County Facility [Member]

Atlanta Facility [Member]

2013 Agreements [Member]

item

sqft

sqft

item

sqft

sqft

item

item

FujiFilm [Member]

defendant

item

sqft

item

sqft

sqft

Commitments And Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Renewal term of supply agreement

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

Termination notice period of supply agreement

'

'

'

'24 months

'

'

'

'

'

'

'

'

'

'

Purchase commitment

'

'

'

'

'

'

'

'

'

'

'

'

'

$22.70

Expense related to antigen inventory not useable for commercial production

46.2

'

'

'

'

'

'

'

'

'

'

'

'

'

Inventory impairment insurance coverage, amount

30

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of operating leases

'

'

'

'

'

'

'

2

'

'

'

'

'

'

Rentable space under lease agreement, in square feet

'

'

'

'

39,937

158,081

179,656

112,915

'

97,365

184,000

'

156,000

'

Additional space subleased, in square feet

'

'

'

'

'

'

'

22,583

'

'

'

'

'

'

Investments securing letters of credit

5.4

5.6

'

'

1.6

'

'

1.1

1.1

1.1

1.5

1.7

'

'

Term of lease, years

'

'

'

'

'10 years

'

'5 years 6 months

'

'

'8 years

'10 years 6 months

'

'10 years 6 months

'

Number of renewal terms

'

'

'

'

1

'

1

'

'

'

5

'

5

'

Renewal term, years

'

'

'

'

'5 years

'

'2 years 6 months

'

'

'

'5 years

'

'5 years

'

Rent expense

8.4

9.6

11.5

'

'

'

'

'

'

'

'

'

'

'

Expected cancellation fees under the Development and Supply Agreement

$4

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of current and former officers who are named defendants

3

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of persons in plaintiff group

30

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock shares purchased by plaintiff group

250

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of estimated shares in plaintiff class

0.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of defendants

3

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of additional defendants

1

'

'

'

'

'

'

'

'

'

'

'

'

'

Commitments_And_Contingencies_2

Commitments And Contingencies (Schedule Of Future Minimum Lease Payments) (Details) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Commitments And Contingencies [Abstract]	'
2014	$9,192
2015	8,859
2016	8,920
2017	5,989
2018	6,166
Thereafter	8,266
Total minimum lease payments	$47,392

Employee_Benefit_Plan_Details

Employee Benefit Plan (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Benefit Plan [Abstract]	'	'	'
Employee contribution rate, maximum	60.00%	'	'
Employee contribution rate, per dollar	50.00%	'	'
Employee individual contribution, maximum	$4,000	'	'
Employer contributions	$2,100,000	$3,800,000	$4,100,000

Quarterly_Information_Summary_

Quarterly Information (Summary Of Unaudited Statements Of Operations) (Details) (USD $)

3 Months Ended

12 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Quarterly Information [Abstract]

'

'

'

'

'

'

'

'

'

'

'

Total revenue

$74,835,000

$68,002,000

$73,315,000

$67,594,000

$85,493,000

[1]

$77,971,000

[1]

$79,992,000

[1]

$82,074,000

[1]

$283,746,000

$325,530,000

$341,613,000

Cost of product revenue

38,476,000

[2]

40,679,000

[2]

43,798,000

[2]

43,375,000

[2]

54,371,000

51,749,000

61,731,000

60,041,000

166,328,000

227,892,000

159,090,000

Gross profit

-3,640,000

[3]

21,049,000

[3]

29,488,000

[3]

24,205,000

[3]

31,084,000

[4]

26,193,000

[4]

18,233,000

[4]

21,931,000

[4]

'

'

'

Loss on inventory impairment

39,992,000

[4]

6,254,000

[4]

'

'

'

'

'

'

46,246,000

'

'

Restructuring, contract termination and asset impairment

7,675,000

1,188,000

-304,000

1,960,000

-36,302,000

[5]

80,994,000

[5]

1,099,000

[5]

-124,000

[5]

10,519,000

45,667,000

38,587,000

Net loss

-88,742,000

-67,215,000

-68,842,000

-72,005,000

-38,695,000

-154,864,000

-96,137,000

-103,914,000

-296,804,000

-393,610,000

-337,806,000

Basic and diluted net loss per share

($0.58)

($0.44)

($0.45)

($0.48)

($0.26)

($1.04)

($0.65)

($0.70)

($1.95)

($2.65)

($2.31)

Impairment related to closing of New Jersey facility

'

'

'

'

'

65,300,000

'

'

'

'

'

Restructuring cost recovery

'

'

'

'

47,400,000

'

'

'

'

'

'

Proceeds from sale of facility

'

'

'

'

$43,000,000

'

'

'

'

$43,000,000

'

[1]

Total revenue for the quarter ended DecemberB 31, 2012 includes a $3.8 million favorable change in estimate related to PHS chargebacks. See Note 2 - Significant Accounting Policies - Revenue Recognition.

[2]

Cost of product revenue for the quarter ended September 30, 2013 has been adjusted to exclude $6.3 million in loss on inventory impairment, which is now separately disclosed as bLoss on inventory impairmentb on the consolidated statements of operations.

[3]

See Note 5 - Inventory for details of losses on inventory impairment recorded in the third and fourth quarters of 2013.

[4]

Gross profit is calculated by subtracting cost of product revenue (including loss on inventory impairment) from product revenue

[5]

Restructuring, contract termination and asset impairment expense for the quarter ended SeptemberB 30, 2012 includes impairment charges of $65.3 million related to our decision to close the New Jersey Facility and the discontinued development of a non-essential computer software project. Upon sale of the New Jersey Facility to Novartis in December 2012, restructuring, contract termination and asset impairment expense for the quarter ended DecemberB 31, 2012 includes the recovery of $47.4 million. The recovery was calculated as the proceeds from the sale of the facility of $43.0 million, plus the release of the facility-specific lease and asset retirement obligations, less the remaining net book value of the New Jersey Facility. Refer to Note 13 - Restructuring, Contract Termination and Asset Impairment.